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Atrial Fibrillation (AF) is the most common sustained arrhythmia; however its underlying 
mechanism is yet to be fully characterised.  Emerging data have elucidated the strong 
correlation of the arrhythmia with uncontrolled cardiovascular (CV) risk factors. Amongst 
these, hypertension is the most common population attributable risk associated with AF. 
However, treatment goals for blood pressure in AF remains undefined. The brachial blood 
pressure is recognised as an important predictor of future cardiovascular events.  
However, as compared to brachial, central blood pressure is more strongly related to CV 
outcomes. Aortic stiffness as a surrogate for persistently high central blood pressure, is of 
independent value in predicting AF outcomes. Further, certain anti-hypertensives can 
have a differential impact on brachial and central blood pressure. This may have 
important clinical implications in ongoing management of hypertension. However, further 
studies are required to demonstrate independent value of targeting central blood 
pressure to improve CV endpoints.  
This thesis evaluates the association of hypertension and aortic stiffness as a surrogate 
for central blood pressure with AF. Chapter 1 provides a comprehensive review of the 
literature linking hypertension (HTN) and AF. Additionally, a clinical assessment tool is 
proposed to better characterise atrial remodelling and end organ injury due to HTN.  Pre-
HTN is not benign and associated with increased risk of developing AF. Chapter-2 
summarises the association of pre- HTN and new-onset AF by presenting the systematic 




reported the independent value of aortic stiffness in predicting CV and mortality 
outcomes. However, its association with new-onset AF is evolving. In Chapter 3, we 
present the systematic review and meta-analysis of all the published prospective trials 
associating increased aortic stiffness with AF, CV and all-cause mortality. Despite its 
adjunctive value, aortic stiffness assessment is sparingly used in clinical CV risk profiling. 
Chapter 4 summarises and critically appraises the methodology adapted by commercially 
available devices to evaluate central blood pressure indices and aortic stiffness to 
improve clinical integration of these tools in ongoing CV risk factor management in AF. 
However, none of these devices has been validated to assess central BP and aortic 
stiffness during AF. In Chapter 5, we present our findings of IMPULSE AF validation study 
(Trial Id: ACTRN12616001225404). It is the first study to evaluate non-invasive central 
blood pressure and aortic stiffness assessment during AF. We validated non-invasive CBP 
indices assessment by SphygmoCor against invasive aortic root pressure and reported 
reliable assessment of CBP indices and aortic stiffness during rate-controlled AF. 
Exaggerated BP response to exercise can unmask pre- HTN and has been associated with 
adverse CV outcomes. Chapter 6 characterises the difference of central and peripheral 
blood pressure indices response to exercise in our AF cohort. As compared to controls, AF 
patients were reported to have normal resting central BP indices. However, during 
exercise impaired conduit arterial compliance was found in AF patients. This may reflect a 
residual aortic stiffness associating AF with persistently high central BP. 
This thesis recognises the additional value of non-invasive central BP indices and aortic 
stiffness assessment to better characterise HTN and its associated end organ injury in AF. 




AF and during exercise. However, further work is needed to establish central blood 
pressure and aortic stiffness as a treatment target to prevent HTN induced CV events.  
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AF:   Atrial fibrillation 
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CV:   Cardiovascular 
HTN:  Hypertension 
PP:   Pulse pressure 
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Epidemiological studies have shown increasing incidence of atrial fibrillation (AF) with 
hypertension (HTN) (1). Despite its recognition as the most prevalent risk factor 
responsible for the development of AF in the population, the target blood pressure (BP) 
concerning primary and secondary prevention of AF is yet to be defined (1). Additionally, 
it is still unclear if the correlation of high BP with increased incidence of AF is linearly 
related or if there is a threshold when atrial remodelling would occur (2, 3). Further, the 
definition of HTN is evolving and optimal treatment goals are still indistinct. Pre- HTN 
defined as a BP range of 120-139/80mmHg is not benign. Studies have reported increased 
risk of cardiovascular (CV) morbidity and new-onset AF with pre-HTN (4, 5). The recent 
updated guidelines are advocating strict blood pressure (BP) control of 120/80mmHg (6). 
However, studies have not shown a consistent trend of better AF outcomes with 
aggressive BP control. (7-11). 
Of note, individuals with HTN often have CV comorbidities and other CV risk factors (12, 
13). Unattended CV risks accelerate the progression from pre-hypertension with 
asymptomatic CV adaptations to established HTN and end organ disease with AF. 
However, this typical pattern of progression is not always seen and individuals with HTN 




CV risk models characterise elderly hypertensive as high risk of future CV events in next 5-
10 years, as compared to vulnerable young with sub-clinical HTN despite their premature 
and predicted long exposure to high BP. Moreover, the significance of temporal variation 
in BP, its response to stress including exercise and the independent role of persistently 
high central high blood pressure leading to aortic stiffness is not very well defined in HTN 
treatment guidelines.  
Given the expanding prevalence of HTN in the community (14), a detailed appraisal of 
pre-clinical manifestations of CV remodelling is warrantied to detect early and subtle 
deviations to better predict hypertension induced end-organ injury and its association 
with AF.  
1.2 GLOBAL AF BURDEN 
Epidemiological parallels are evident with the rising burden of AF and HTN (1, 15, 16). 
Despite reported racial and regional variabilities, the prevalence and incidence of AF are 
increasing with the addition of approximately 5 million new cases per year globally (17). 
The age-adjusted, worldwide prevalence of AF in 2010 was reported to be 0.5% and 33 
million individuals were found to be affected by the condition (17, 18). As age is a major 
contributor to AF burden, an increased arrhythmia prevalence of 8-15% was reported in 
elderly population (19). In a recent review, Wong et al. projected a 12-fold increase in AF 
incidence in Australasia as compared to their American counterparts with an estimate of 
49 million men and 23 million women affected by AF by the year 2050 (20). The tide of AF 
will continue to rise because of the ageing population, increasing prevalence of 
hypertension, better arrhythmia detection, the obesity epidemic and improved survival 




portends a 5-fold risk of disabling stroke (22). AF is associated with a 3-fold increased risk 
of heart failure (23) with doubling of dementia risk (24) and increased all-cause mortality 
(25). Although aggressive risk factor modification is recognised as an important pillar of 
AF treatment (26), the lack of established BP targets highlights gaps in the evidence. 
Hence, studies to define BP targets are urgently required to prevent HTN induced pre-
mature end organ injury predisposing to AF.  
1.3 ESCALATING BURDEN OF HTN- IMPACT OF REVISED AHA GUIDELINES 
Recently updated American College of Cardiology (ACC)/American Heart Association 
(AHA) guidelines reduced the threshold to diagnose HTN in order to prevent, recognise 
and promptly manage the end-organ injury, incurred by BP levels previously classified as 
"pre-hypertension". These guidelines have categorised BP into normal (less than 
120/80mmHg), and elevated (systolic 120-129 and diastolic < 80mmHg). HTN was further 
characterised as stage I (systolic 130-139 or diastolic 80-89mmHg) and stage II (≥ 
140/90mmHg) (27). The re-classification of HTN by AHA exposes the magnitude of health 
burden posed by HTN. These guidelines strongly promote lifestyle modification with 
prompt introduction of pharmacotherapy in individuals not achieving treatment targets. 
With the introduction of these updated guidelines, nearly half of the US adult population 
(46%) is deemed to have HTN (27). The prevalence of HTN was found to be 26% in 
Australian Adult population. The HTN was defined as brachial BP of >140/90 mmHg or use 
of medications to lower the BP (28). However, by adapting ACC/AHA guidelines with a BP 
cut-off point of 130/80 to diagnose HTN, the prevalence of the condition in Australia is 
almost doubled to 51% (29). The impact of the increasing prevalence of HTN will be more 




raised about the cost-effectiveness and potential side effects of anti-hypertensive 
treatment offered to individuals labelled as hypertensive by adapting ACC/AHA 2017 
guidelines.  
Despite the proposed holistic approach with focus on management of co-morbidities and 
socioeconomic stressors, fundamental questions concerning target BP and its supporting 
evidence remain. The European Society of Cardiology (ESC)/European Society of 
Hypertension (ESH) suggested instigation of pharmacotherapy in individuals with an 
average resting day time BP of ≥140/90 as compared to more aggressive approach 
adapted by ACC/AHA (30). Interestingly, less than 20% of the recommendations by these 
guidelines are supported by strong evidence base (Class I, Level of Evidence). The strong 
advocacy for BP targets <130/80 for a general population with CVD risk of >1%/year is 
largely based on Systolic Blood Pressure Intervention Trial (SPRINT). However, SPRINT 
investigators excluded diabetics, previous strokes and majority of patients commenced 
on anti-hypertensive treatment. Concerning outcomes, a relative risk reduction of 16-18% 
by aggressive BP control (<130/80 mmHg) was only recorded for stroke and major 
adverse cardiovascular events (MACE).  
From a clinical perspective, treatment of hypertension must be customised according to a 
cumulative hazard due to the presence of co-existing CV risks including diabetes, 
obstructive sleep apnoea, obesity and dyslipidaemia. The AHA guidelines recommended 
pharmacotherapy for patients with stage I HTN with an atherosclerotic cardiovascular 
disease (ASCVD) risk of >1%/year (27). In general, these risk assessment tools including 
the Framingham risk calculator are derived from epidemiological studies and tend to 




outcomes (8, 32). The beneficial impact of targeting BP 120/80 was mostly recorded for 
individuals with 18% risk of CVD over 10 years. Hence, this 1% /year CVD risk is arbitrary 
and has to be further supported by outcome studies.  Additionally, the standardised 
methodology to estimate BP must be established across the clinical trials to minimise the 
inter and intra-observer variability. Notably, these guidelines did not consider AF as a 
potential marker of end-organ injury in HTN. Furthermore, the adjunctive but 
independent role of exaggerated BP response to exercise and conduit arterial stiffness as 
a surrogate of persistent central high BP, was not explored.    
1.4 ASSOCIATION OF HYPERTENSION WITH AF 
1.4.1  A Complex Pathophysiological Nexus 
HTN has an independent, strong and graded association with AF (4, 33). The left 
ventricular hypertrophy, left atrial dilatation, central arterial stiffness and endothelial 
dysfunction are important mediators, associating HTN with AF (16, 34-37). Despite the 
observed strong correlation between AF and HTN, the underlying pathophysiology is still 
incompletely understood. Moreover, in hypertensive individuals, development of AF is 
not widely recognised as an end organ insult.  
Several experimental HTN models have evaluated the connection between HTN and AF 
(Table -1.9.1) (38-40). HTN triggered structural and electrophysiological transformation of 
left atrium (LA) (39). Moreover, the extent of the LA remodelling was found to be 
dependent upon the duration of hypertension (41, 42).   
Electrophysiologically, the remodelled LA due to HTN exhibited gap-junction 




slow conduction velocity that promote re-entry to sustain and perpetuate AF (43, 44). 
Hemodynamically and structurally, sustained high blood pressure reduces left ventricle 
(LV) compliance and increases the left atrial stretch resulting in dilatation of the atria (45). 
An impaired left ventricle (LV) diastole resulted in escalated pulsatile load and left atrial 
dilatation predisposing to AF (46, 47). In addition, increased ventricle stiffness led to 
activation of renin-angiotensin-aldosterone axis (RAA)and sympathetic system. HTN also 
promotes atrial remodelling through activation of composite signalling pathways 
involving angiotensin, growth factors, inflammatory cytokines, and endothelin resulting in 
atrial interstitial fibrosis, electro-anatomical heterogeneity and dysfunctional cellular 
calcium handling (43).  Moreover, paroxysms of AF further impair LA function and 
facilitate AF through ongoing structural and electrical adaptations. The altered atrial 
substrate with the combination of electrical, anatomical and cellular transformation can 
potentially instigate and sustain AF in hypertensive animals (21, 43). These findings from 
the animal studies can help explain the increased risk of AF reported in hypertensive 
individuals with dilated LA and increased LV thickness.  
A number of studies including Losartan Intervention For Endpoint Reduction in 
Hypertension (LIFE) reported the association of HTN and electro-anatomical LA 
remodelling, manifested as LA dilatation, with increased AF, heart failure and mortality 
(45, 48, 49).  
Interestingly, the co-existence of CV risks including obesity and OSA with HTN escalate the 
electro-anatomical transformation of LA with changes of the regulatory mechanisms 




association is reported between LA adaption and intensity as well as chronicity of these 
risks driving the chamber transformation (50).  
1.4.2 Hypertension and New-Onset AF 
The majority of the AF cases are a consequence of electro-anatomical remodelling of the 
left atrium, precipitated by a multitude of cardiovascular risks (34). Epidemiological 
studies have established hypertension as a predominant yet modifiable factor in the 
development of atrial fibrillation (23, 51). However, it is not clear if the association of AF 
with HTN is linear or threshold dependant. In approximately 70% of patients, HTN was 
seen with other cardiovascular morbidities such as diabetes, chronic kidney disease and 
stroke (51).  
Even a marginally increased BP of >130/80 mmHg was found to be associated with 40% 
escalated risk of adverse CV outcomes (11, 13). In otherwise healthy individuals, an 
independent association of pre-HTN (129-139/80 mmHg) with incidental AF has been 
reported by population studies (4, 10, 52). A 1.5-fold increase in incidental AF was noted 
in middle age Norwegian men with sustained BP of 129-139/80 mmHg (53). Similarly, a 
28% increased risk of new-onset AF was described by investigators of Women’s Health 
Initiative Study in patients with BP of >130/80mmHg (52). A recent epidemiological study 
has reported the evolution and impact of BP on risk of development of incidental AF over 
a period of 15years. As compared to their normotensive (BP 120/80mmHg) counterparts, 
individuals with persistent HTN (BP 140/90mmHg) or increased resting pulse pressure 
were shown to have two-fold increased risk of new-onset AF (54). The Atherosclerotic 
Risk in Communities (ARIC) study reported HTN as the most important contributor, 




Study of Atherosclerosis (MESA) recorded a graded association between BP and AF. Over 
a 5-year follow up period, one-third of the MESA cohort developed HTN with a reported 
4-fold increased risk of AF. As compared to normal BP, even pre- HTN was associated with 
80% higher risk of AF (5).  
Hypertension is also widely prevalent in AF patients. Recently reported trials involving 
Novel oral anti-coagulants have reported a very high (> 75%) incidence of HTN in their AF 
cohorts. The incidence may well be under reported by these studies, as HTN was defined 
as persistent BP of >140/90mmHg during screening in participants not on active anti-HTN 
treatment. (55-57).  
1.4.3 BP Targets for Patients Undergoing AF Ablation 
Current literature supports an aggressive approach to target BP in AF to improve the 
success of catheter ablation, reduce progression of the atrial remodelling and HTN related 
cardiovascular complications including escalated risk of stroke, bleeding, renal 
impairment and heart failure. (47, 58) However, optimal blood pressure treatment 
targets post AF ablation are yet to be defined. The SMAC-AF study did not reveal any 
significant advantage of achieving mean BP target close to 120/80mmHg as compared to 
130/80mmHg with no differences in AF outcomes post ablation over 3-6 months follow 
up. (46) The same observation was reported by post-hoc analysis of AFFIRM during a 
mean 6 years follow up of rhythm control arm. (59)  
As AF is a result of multiple modifiable risk factors, it is likely that studies examining a sole 
risk factor may be inadequate. The above-mentioned studies are likely to lack statistical 
power to detect any differences especially with the short follow-up duration in the SMAC-




management approach that addresses all the modifiable risk factors (e.g. sleep apnoea 
management, alcohol reduction, glycaemic control, weight management and exercise) to 
prevent AF in conjunction with high BP treatment (34). Second, brachial blood pressure is 
not a sensitive indicator of central pulsatile load an atrium is subjected to. Perhaps, 
assessment of central BP and aortic stiffness indices may provide a better therapeutic 
target. Third, better risk stratification tools may be required to expose sub-clinical 
hypertension induced end organ and CV remodelling.  
In addition to conventional cardiovascular risks, discrete factors including obstructive 
sleep apnoea, high pulse pressure, aortic stiffness, obesity and genetic susceptibility are 
reported to accelerate atrial remodelling, development of AF  and poor outcomes post 
ablation (Figure-1.8.1), (60-62). Therefore, patients with elevated BP require extensive 
risk profiling to expose and target relatively early signs of end-organ insult including 
impaired atrial, ventricular and vascular compliance to improve their clinical outcomes.  
1.5 IMPORVED CHARACTERISATION OF HTN INDUCED END-ORGAN 
INJURY AND ITS ASSOCIATION WITH INCIDENTAL AF 
 
 A novel clinical approach in addition to the conventional CV risk stratification, is 
therefore needed to better characterise sub-clinical manifestation of end organ injury to 
improve predictability of new-onset AF in the hypertensive patients (Table 1.9.2). 
1.5.1 Left Atrium Remodelling Assessment and its Association with AF 
Left atrium (LA) is the most posteriorly located of the cardiac chambers. The pulmonary 
veins traverse the relatively fixed posterior wall of the LA with left veins positioned 
slightly higher than the right. Electro-anatomical characteristics of pulmonary veins (PVs) 




muscular sleeve at the veno-antral junction (63). Despite the reported strong association 
of  LA enlargement with AF, stroke and mortality (48, 50, 64), the most commonly used 
risk scores predicting thromboembolic complications in AF, including CHA2DS2-VASc, do 
not include LA dilatation in their stratification scheme (3).  
In general, LA size is derived by anteroposterior diameter from a parasternal long-axis 
view with standard 2-dimensional echocardiography. But the volume assessment of LA is 
more useful, as LA dilatation can be asymmetrical due to the relatively fixed posterior 
wall (48). The normal reference range for LA volume indexed to body surface area (BSA) is 
16-34ml/m2 (65) . However, the electrophysiological transformation precedes atrial 
dilatation as one-fifth of the hypertensive patients with AF demonstrated preserved LA 
size (66). In AF patients with preserved LA volume, cardiac magnetic resonance imaging 
(CMR) with late gadolinium enhancement can be useful to characterise LA and its scar 
burden to help predict arrhythmia recurrence. Based on LA late gadolinium 
enhancement, a grading system for LA fibrosis was proposed by DECAAF study 
investigators (67). Stage I has <10% fibrosis of LA wall as compared to stage IV with >30% 
fibrosis burden involving the LA wall.  Each 1% increase in LA fibrosis was found to be 
independently associated with 6% increased risk of AF recurrence post ablation at 325 
days follow-up (67). 
Concerning AF outcomes, assessment of LA physiology can expose sub-clinical 
remodelling not obvious on anatomical description of the chamber (66, 68). LA is a 
dynamic structure, which expands to act as a reservoir during LV systole, and works as a 
passive as well as an active conduit during early and late LV diastole respectively. Doppler, 




including LA appendage (LAA) ejection velocity, LA emptying fraction (LAEF), early to late 
mitral inflow velocities ratio and tissue Doppler to quantify LA strain. Although a 
standardised approach regarding LA physiology assessment is yet to be adopted, the 
normal reference value of LAEF and LAA ejection velocity is defined as 45% and 40cm/sec 
respectively (66).  A detailed structural and functional evaluation of LA in patients with 
pre-hypertension, HTN and “lone” AF, can be valuable to illustrate pre-mature 
remodelling of LA in order to instigate aggressive risk factor modification to improve AF 
outcomes. A list of common clinical methods to characterise LA is detailed in Table-2.  
1.5.2 Left Ventricle Hypertrophy Screening to Predict New-Onset AF  
HTN induced left ventricle hypertrophy (LVH) is an increase in LV mass or thickness, due 
to sustained amplification of pulsatile load attributable to high blood pressure. In general, 
M-mode and 2-dimensional echocardiography is used to estimate LVH. In men, the LVH is 
defined as LV mass of >115g/m2 indexed to the BSA by linear measurements and 102g/m2 
using 2-dimensional echocardiography. On the other hand, in women, the upper 
reference limit of normal LV mass is 95g/m2 by linear measurements and 88g/m2 by 2-
dimensional echocardiography (65). As a modifiable factor, LVH is strongly associated 
with increased incidence of AF, independent of baseline BP. Unattended CV risks such as 
obesity and OSA, can also lead to early and progressive changes in LV mass resulting in 
LVH, in addition to HTN (69, 70). In general, LVH results in increased LA stretch 
subsequent to diastolic impairment and reduced LA emptying. The persistently increased 
LA stretch results in chamber dilatation, which is found to be independently associated 
with incidental AF (68). Moreover, persistent hemodynamic LV overload activates the 
neurohormonal, oxidative and inflammatory pathways which further remodel the cardiac 




wavering from 10-77%. Enrolment of a heterogeneous population with distinct CV risk 
profiles help explain the reported differences in the prevalence of LVH. A graded 
association was observed concerning the presence of LVH and CV risks, the lowest (9-
17%) being reported for population-based studies and the highest (60-77%) for elderly 
hypertensive patients with multiple CV morbidities (71, 72). In general, echocardiography 
is used to confirm the presence and pattern of LVH. The pattern of LVH can be concentric 
or eccentric. The latter confers more restrictive diastolic filling and have stronger 
association with AF recurrence (73).  
Importantly, sustained hypertension can cause sub-clinical LVH that is associated with 
increased incidence of new-onset AF as reported by MESA study (74). LVH is also 
correlated with poor outcomes in patients with known AF including post ablation (69). Off 
note, LVH is a modifiable factor and regression of LVH translated into improve AF and CV 
outcomes independent of blood pressure control (75). Therefore, LVH screening by 
echocardiography in patients with sub-clinical HTN is valuable to characterise blood 
pressure induced premature end-organ injury and possible prevention of AF by targeting 
BP aggressively and prompt attention to other risk factors. 
1.5.3 Role of Exercise-Induced Arterial Hypertension (EIAH) 
In general, baseline BP is recorded after 5-10 minutes rest to preclude amplified BP 
response to “stress”. The predictive relevance of exaggerated BP response to exercise in 
AF is still unclear. Moreover, hypertensive response to exercise is not very well defined. A 
meta-analysis of 12 longitudinal studies described exercise-induced arterial HTN (EIAH) as 
a systolic pressure recording of 230mmHg on moderate exertion (76). EIAH to moderate 




BP recording and conventional CV risk factors (76). EIAH is shown to be associated with 
LVH, which is a major driver of atrial remodelling and AF (77, 78). Exaggerated BP 
response to exercise can help identify patients at risk of developing HTN with premature 
CV remodelling including AF. Further, estimation of BP indices response to exercise 
including pulse pressure assessment can unmask residual central arterial stiffness that is 
associated with increased risk of new-onset AF and poor outcomes post AF ablation (35, 
61).  
1.5.4 The Central Blood Pressure and Conduit Arterial Compliance Assessment 
As compared to brachial blood pressure, central blood pressure (CBP) and aortic stiffness 
assessment is more relevant to estimate central pulsatile load and demonstrated improve 
predictability of new-onset AF (79). Population studies revealed that up to 70% of the 
participants characterised as pre-hypertensive on brachial BP assessment, actually had 
central high BP (80). Despite good brachial BP control, patients with impaired central 
arterial compliance have poor AF outcomes and are at increased risk of adverse CV events 
(81). Historically, measurement of CBP required central arterial catheterisation for direct 
manometry. However, a variety of cuff based devices can be used to estimate CBP as well 
as aortic pulse wave velocity (aPWV) to calculate aortic stiffness, non-invasively (82).  
In general, non-invasive aortic stiffness assessment is performed by aPWV appraisal, 
central pulsatile load and ascending aortic distensibility estimation. The aforementioned 
methods essentially estimate aortic response to pulsatile pressure and volume load 
during ventricular-arterial coupling. As the conduit artery remodels, the aPWV increases, 
the pulse pressure amplifies and proximal aorta distensibility diminishes (83). The aPWV 




and dividing it by transit time. The carotid and femoral arteries are the most common 
vascular points used to determine carotid-femoral PWV (cf-PWV) and is recognised as a 
“gold standard” to calculate the aortic stiffness (30). However, the independent 
association of increased cf-PWV and reduced aortic distensibility with poor AF outcomes 
is yet to be established. Notably, increased pulse pressure (>60mmHg) as a surrogate of 
aortic stiffness is found to be independently associated with increased incidence of AF 
and also linked to worse outcomes post AF ablation (61, 83). Pulse pressure (PP) 
estimation can be easily derived by subtracting systolic from diastolic BP and particularly 
useful in middle aged (40-60 years) individuals to expose vascular remodelling and 
increased risk of AF. As a modifiable factor, pre-mature central arterial stiffness 
estimation can offer improved risk factors modification in patients with AF(61). 
Nonetheless, further studies are required to illustrate better AF outcomes by targeting 
central blood pressure indices.  
1.5.5 Appraisal of Endothelial Dysfunction in Elevated BP 
Though the precise sequence of events leading to hypertension-induced end-organ injury 
is yet to be explicated, increased incidence of endothelial dysfunction is described in 
individuals with HTN (84, 85). Endothelial dysfunction is a structural or functional breach 
of the vascular inner lining with a predilection to inflammation and thrombosis. Though 
not performed routinely in clinical settings, endothelial dysfunction is a common finding 
in HTN induced micro and macro-vascular remodelling. It can be assessed non-invasively 
by flow-mediated vascular dilatation (FMD) (86) and is being increasingly described in AF 
patients with pre-hypertension and HTN (84, 85, 87). FMD is a direct marker of nitric 




one unit decrease in FMD is associated with 16% escalated risk of hypertension 
independent of age and baseline BP (88).   
Systemic endothelial dysfunction is also well recognized in patients with persistent atrial 
fibrillation and left atrial remodelling (86). The exact mechanism associating left atrial 
remodelling with endothelial dysfunction is under considerable debate. It is postulated 
that irregular heart rate and turbulent flow with abruptly changing vascular wall stress 
along with systemic inflammation due to uncontrolled CV risks in AF, resulted in reduced 
nitric oxide assembly and decrease endothelial nitric oxide expression. The nitric oxide 
activity can be gauged by decline in plasma nitrite/nitrate levels in AF (85, 89). The 
systemic inflammation, neurohormonal activation through renin aldosterone and 
angiotensin pathway with ongoing oxidative stress are other possible mechanisms linking 
endothelial dysfunction to vascular and atrial remodelling (43). The angiotensin 
convertase enzyme inhibitors have shown a modest decelerating effect on vascular 
remodelling, independent of CV risk factors by inhibiting renin-angiotensin and 
aldosterone system activation and reducing systemic inflammation promoting atrial 
fibrosis (90). As a reversible factor, endothelial dysfunction can be linked to the 
pathogenesis of HTN induced AF. Therefore, the functional endothelial assessment can 
improve characterisation of sub-clinical HTN and in “lone” AF patients.  
1.5.6 High Urinary ACR and AF Incidence   
The high urine albumin: creatinine ratio (ACR) is defined as >2.5mg/mmol 
and >3.5mg/mmol in men and women respectively. Increased urinary ACR is a marker of 
renal micro-vascular injury and endothelial dysfunction that can be detected in elevated 




graded as per quantitative urinary protein leak per mg of creatinine, categorised as mild 
(ACR<3mg/mmol), intermediary (ACR 3-30mg/mmol) and severe (>30mg/mmol) (91). Pre-
HTN range of  BP (≥ 130/80mmHg) is independently associated with a twofold increased 
risk of albuminuria (92). Furthermore, a graded association between urinary ACR and new 
onset of AF independent of baseline eGFR was reported by epidemiological studies (93, 
94).  The urinary ACR estimate is universally available and can be easily incorporated in 
risk profiling tools to predict AF particularly in patients with moderate to high burden of 
CV risk. However, further prospective studies are required to explore the independent 
association of increased urinary ACR with escalated risk of AF.  
1.5.7  Screening for Hypertensive Retinopathy  
A graded association is noted between hypertensive retinopathy and incidental AF (95). 
Retinopathy is also correlated with proteinuria, LV diastolic dysfunction and enlarged LA 
in HTN (95). Retinopathy represents microvascular remodelling due to endothelial 
dysfunction, and hypoxic vascular injury consequential to persistent high blood pressure.  
Early HTN induced retinopathy presents as segmental or generalised arterial sclerosis 
characterised as arterio-venous (AV) nipping or "silver wire arterioles" respectively. A 
further breach of retinal vascular integrity leads to oedema and retinal haemorrhages. In 
patients with sub-clinical HTN, retinal screening can be a helpful tool to improve risk 





1.6 PREVENTION OF AF- ROLE OF HTN and CV RISKS MANAGEMENT  
1.6.1 HTN and CV Risk Stratification in AF  
Epidemiological studies have established the role of multivariate risk prediction models to 
estimate overall CVD and AF risk in order to guide therapy (96). Factors including HTN, 
diabetes, and smoking are direct causes of CVD. Hence, they are defined as “major” risks 
(3). In general, individuals are graded into low, intermediate or high risk for future CVD 
events by employing a multivariable risk stratification tool (3). In addition to the patients 
requiring ongoing secondary prevention for CVD, individuals with more than one 
established major CV risk, are also categorised as “high” concerning future CV events. 
However, BP poses a dynamic risk and this continuum was neatly illustrated by 
Prospective Studies Collaboration, reporting doubling of cardiovascular and all-cause 
mortality risk for every increase by 20/10mmHg in BP, above a baseline of 115/75mmHg 
(7). The aforementioned observation was validated by a number of studies, reporting the 
association of elevated BP with incidental AF (4, 10, 52, 53). In addition to conventional 
cardiovascular risks, discrete factors including obstructive sleep apnoea, high pulse 
pressure, aortic stiffness, obesity and genetic susceptibility are reported to accelerate 
atrial remodelling and development of AF (Figure-1.8.1), (60-62). Nearly half of the stroke 
and ischemic heart disease (IHD), incidence can be attributable to systolic BP >130mmHg. 
However, only 50% of these individuals met the criteria for high blood pressure 
intervention as per current guidelines (97, 98). Importantly the SPRINT study recorded a 
25% reduction in CVE and mortality in non-diabetic individuals with estimated CVD of 
1.8%/year (9). However, the HOPE III study could not confirm SPRINT observations in 
participants with low (<10%) 10-year CVD risk (99). Therefore, BP treatment requires a 




target. Furthermore, our current practice of CV profiling is based on the algorithms, 
stating 5-10 years risk scores that shifts the focus towards elderly with increased burden 
of CV risks.  
Despite their stratification as “low risk”, elevated BP in relatively younger subjects 
requires further attention to tease out premature CV remodelling by using novel 
strategies including aortic stiffness assessment to better predict morbidity and mortality 
outcomes. The younger patients with sustained pre-HTN are more prone to develop end-
organ injury including AF because of their relatively prolonged exposure to chronically 
elevated pulsatile load (12). The treatment regime must account for multiple CV risks, 
present in the individuals with pre-HTN and established HTN. This customised strategy is 
cost effective and will help evolve BP management, guided by individual risks rather than 
arbitrary cut-points. This approach my help delivers potential benefits to each patient 
with the reduction in undesirable effects of interventions.  
1.6.2 Risk Factor Management (RFM) to Prevent AF   
 Many studies focusing on underlying AF mechanisms have improved our understanding 
on the factors contributing to adverse electro-anatomical LA remodelling and AF 
development or sustenance (37, 38, 41, 43, 44). This approach helped identify the gaps in 
our knowledge and established the need of ongoing risk factor modification in AF 
management to improve outcomes. Investigators have recognised congestive heart 
failure (CHF), diabetes, HTN, LVH, coronary artery disease (CAD), obesity, smoking and 
valvular heart disease (VHD) as predominant modifiable risks ensuing accelerated electro-
anatomical atrial remodelling followed by poor outcomes in AF (3, 100). As compared to 




However, due to its prevalence, HTN remains the predominant population-attributable 
risk driving the incidence of AF (21, 34, 45). In recent years, obesity, as a modifiable 
factor, is also recognised as a major driver of atrial remodelling (26, 101). Notably, 
published evidence demonstrated weight loss and aggressive risk factor management 
with target BP of <130/80 at rest and 200/100mmHg during exercise, as a key to improve 
AF outcomes in patients with BMI ≥27 Kg/m2. A sustained weight loss of ≥ 10% with 
ongoing aggressive risk factor management in AF patients with a baseline BMI of ≥27 
Kg/m2 has a six-fold increased probability of arrhythmia-free survival over long-term 
follow-up of 5 years than those who gained weight or lost <3% of weight (101). The 
aforementioned observations led to the development of a customised and goal-directed 
team approach in AF management by keeping a primary focus on patient education, 
weight loss and aggressive risk factor modification (101, 102). The structured risk factor 
management programme was clinically and cost effective (103).  The beneficial effects of 
weight loss were extended to the metabolic profile of the indexed patients with reported 
improvement in lipids, HbA1c, OSA and blood pressure control (104). 
Nonetheless, it is not known that aggressive risk factor management carries additional 
hard endpoints benefits beyond AF outcomes including mortality, stroke, myocardial 
infarction and heart failure.  
1.6.3 Pharmacotherapy in HTN Patients to Prevent AF 
The close association of HTN with AF pose the opportunity to focus on HTN, as one of the 
major risk factors to prevent new onset and recurrence of AF. Defining HTN treatment 
goals to prevent AF is still a challenge as trial participants display significant heterogeneity 




In younger patients with increased risk of CVD and premature cardiovascular remodelling, 
a more meticulous lifestyle change to address CV risk factor management and aggressive 
blood pressure control can potentially improve outcomes (9). Patients with left ventricle 
hypertrophy (LVH) with LA remodelling  and/or left ventricle systolic dysfunction should 
be preferentially considered for  angiotensin enzyme inhibitors or angiotensin receptor 
blockers (ARBs), as they are reported to be more effective (relative risk reduction of 25-
35%) in primary prevention of AF (105, 106). Likewise, the use of beta-blockers can help 
maintain sinus rhythm in high risk population with history of myocardial infarction, left 
ventricle hypertrophy and systolic dysfunction (107). As compared to angiotensin 
receptor blockers, amlodipine was reported to be less effective in preventing AF (108). 
However, verapamil was found to be more effective in secondary prevention of AF (109). 
Notably, there is limited data to support the use of angiotensin converting enzyme 
inhibitors or angiotensin receptor blockers for secondary prevention of AF in hypertensive 
patients (110). The GISSI-AF trial showed no additional benefit of adding Valsartan to 
prevent recurrent AF post cardioversion (111).  This highlights the importance of more 
extensive profiling of at-risk individuals to explore subclinical insignias of cardiovascular 
injury with the prompt introduction of aggressive risk factor modification and appropriate 
pharmacotherapy.  
The CV risks including BP is a continuum and patients with sustained pre-HTN are more 
likely to develop HTN. Therefore, screening for sub-clinical CV disease in addition to the 
conventional risk stratification as illustrated (Figure-1.8.2), can provide us with a window 
of opportunity to act promptly in order to prevent established clinical and more advanced 




established, its response to aggressively targeting BP varies according to the intensity of 
underlying CV remodelling. For example, a “J” curve association between BP and coronary 
perfusion is reported by targeting BP close to 120/80  in patients with advanced HTN and 
coronary artery disease (112). Therefore, individuals with pre-HTN with increased CVD 
risk should be offered an aggressive risk factor management and early intervention to 
achieve BP targets to help alleviate the burden of AF and CVD.  
1.7 CONCLUSION 
The rising tide of HTN and AF goes hand in hand with the increasing obesity and ageing 
population. Sustained HTN leads to electro-anatomical transformation of atria due to 
elevated central pulsatile load resulting in chronic atrial stretch and its neurohormonal 
sequelae. The close pathophysiological link between HTN and AF highlights the 
importance of recognising AF as a marker of an end organ insult in hypertensive 
individuals requiring tighter BP control. A sustained adherence to CV risk factor 
modification with prompt introduction of pharmacotherapy can potentially transform the 
natural history of pre-HTN/elevated BP and its attributed CV risks. However, further 
prospective studies are required to define blood pressure targets in AF and establish the 
role of detailed CV risk profiling to unmask sub-clinical disease in order to translate it into 

















Table 1.9.1: Details of Animal Studies Illustrating Propensity of 
Hypertensive Hearts to Develop AF 
 










Model Parameters Studied End Points in HTN Model 






by partial constricting 
of ascending aorta) 
LA fibrosis and 
dilatation. Pacing 
induced AF 
Increased fibrosis and 
conduction heterogeneity, 
Dilated LA, Increased 
duration and incidence of 
AF 
 
Lau et al  
(42) 
Spontaneously 





characteristics of LA in 
15-month old 
spontaneously HTN rat  
Electro-anatomical 
properties of LA. AF 
inducibility  
Progressive increased LA 
fibrosis and higher AF 
inducibility with 
macrophages infiltration in 
15-month old HTN rats  








Hypertrophy and fibrosis 
of atrial myocyte. Pacing 
induced AF, LA 
conduction velocity 
Conduction heterogeneity 
with increased AF 
inducibility 








dysfunction & fibrosis. 
AF inducibility & LA 
conduction velocity at 
5,10 and 15 weeks of 
HTN 
Sustained HTN (>10wks.) 
was associated with 
increased LA conduction 
heterogeneity and fibrosis 
resulting in increased 
duration of induced AF  
Choisy et al 
(40) 
Spontaneously 





characteristics of LA 
Induction of 
tachyarrhythmia and LA 
fibrosis at 3 and 
11months 
As compared to controls 
and 3 months old HTN rats, 
Increased LA fibrosis and 
tachyarrhythmia induction 
were seen in 11months old 




Table 1.9.2: CV Risk Profiling of Patients with Elevated BP in Addition to 
Conventional Stratification 
 
(AAD= ascending aorta distensibility, BP= blood pressure, BSA= body surface area, CF PWV= carotid-femoral 
pulse wave velocity, CMR= cardiac magnetic resonance imagining, 2DE=Doppler echocardiography, eGFR= 
estimated glomerular filtration rate, F= female, HTN= hypertension, LAA=left atrial appendage, M= male, 
PP=pulse pressure) 
End-organ Parameter Assessment Method Normal value 




LA diameter /BSA 
(cm/m2) 
2DE and CMR 1.5-2.3cm/m2  (65) 
LA volume indexed to 
BSA (ml/m2) 
2DE and CMR 34ml/m2 (65) 




LA emptying fraction 
(LAEF) 
2DE, CMR LAEF >45%(66) 
LA appendage velocity 
2DE 
 
LAA velocity 40cm/s 
 
LA strain 




Reservoir Strain 39% (114) 
Conduit Strain 23% (114) 














LVM 2DE method 2DE 
F  (44-88)(65) 
M (50-102)(65) 
 
Renal screening in 
patients with normal 



















Surrogate for central 
high blood pressure 
CF PWV 5.4 - 9.9m/s (79, 115) 
PP <60mmHg (79) 
AAD 8.9 ± 3.6 (10-3 mmHg-1) (115) 
Exercise induced 




























Association of Pre-Hypertension and New-Onset of Atrial 
Fibrillation: A Systematic Review and Meta-Analysis 
 
2.1  INTRODUCTION 
A growing body of evidence is associating pre-hypertension, defined as BP range of 120-
139/80-89 mmHg, with new-onset atrial fibrillation (AF).  Pre-HTN is closely associated with 
stroke and cardiovascular (CV) morbidity (116, 117). Notably, the updated American Heart 
Association (AHA) guidelines acknowledged BP > 120/80mmHg as “elevated” and 
recommended robust lifestyle modification with prompt introduction of pharmacotherapy 
in patients with persistently high BP of more than 130/80mmHg with >1% annual risk of 
cardiovascular events. However, a consistent pattern of AF reduction or improved 
cardiovascular outcomes by intensive BP control is yet to be seen (7-11). With the 
increasing evidence base establishing a link between pre-hypertension and AF, we sought 
to perform a systematic review and meta-analysis to determine the strength of these 
associations in relation to the development of new-onset AF.  
 
2.2  METHODS 
2.2.1 Literature Search 
The meta-analysis was registered with PROSPERO (149706). With the help of an 
experienced librarian, an online search of PubMed and EMBASE databases was performed 




“elevated blood pressure” or “blood pressure” AND “events”, “atrial fibrillation”, “atrial 
arrhythmia”, “outcome”. Duplicate citations were removed.  
2.2.2 Inclusion and Exclusion Criteria 
We included prospective longitudinal studies published in English with more than 50 
participants and a minimum follow-up duration of 1 year that employed standardized 
methodology to assess blood pressure to quantify pre-HTN and its association with new-
onset AF (Table-2.9.1). In addition, a manual search of the bibliographies of the retrieved 
articles was performed to identify all relevant studies. We excluded reviews, editorials, case 
reports, letters and conference abstracts associating   AF incidence with blood pressure 
levels. However, their reference lists were manually searched for relevant publications.  
2.2.3 Data Extrapolation 
The literature search, study selection and extraction of the data set was performed by two 
authors (KBK and AM) independently. The quality of the studies was gauged by modified 
Newcastle-Ottawa scale by two independent reviewers (KBK and AM) as listed in Table 
2.9.2. Divergent views were resolved by consensus. Data was collected on cardiovascular 
risk profiling of the participants, follow-up duration, and incidence of new-onset AF. The 
reported quantitative risk estimation for new-onset AF was used for statistical analysis to 
derive a cumulative hazard profile for pre-HTN.  
2.2.4 Statistical Analysis 
Our search resulted in a list of studies with comparable populations and acceptable 
distribution of reported BP range. Adjusted hazard ratios (HR) were used to report risk 
comparison in the studies. Pooled HR and 95% confidence intervals were calculated by 
random effects meta-analysis technique. The most adjusted model in each study was 




cardiovascular disease, smoking, diabetes and left ventricle hypertrophy. All the studies 
have adjusted for age, gender, BP, smoking and left ventricle hypertrophy as shown in table 
2.9.1. A 2-tailed value of p<0.05 was considered statistically significant. Furthermore, 
heterogeneity across studies was assessed by using I2 statistic. A Funnel plot was used to 
examine the heterogeneity in reported estimates and publication bias by illustrating effect 
size against standard error (Figure 2.8.1).  
 
2.3  RESULTS 
2.3.1 Literature Search and Study Selection 
Initial online search of PubMed and EMBASE database retrieved 15,530 studies, which were 
narrowed down to 5 relevant articles as per eligibility criteria (Figure 2.8.2). Out of the 
above 5116 were found to be duplicate references. In total, 10,414 were screened for 
abstracts and titles. Out of those, 10,390 were excluded as the outcome of interest was not 
reported. The remaining 24 studies were accessed for full text review to confirm their 
eligibility as per reported criteria in section 2.2.2. We have to further exclude 19 studies as 
the pre-defined outcome was not reported by them. Finally, the 5 remaining articles were 
found to be eligible to include in the analysis.  
2.3.2 Study Population 
The five studies that reported on the association between pre-HTN and incident AF 
recruited 4,346,851 participants (48% male) with a mean age of 517.5 years over a median 
follow-up duration of 12.4 years (Interquartile Range [IQR] 6.1-14yrs.). The included studies 
were all community based. Only 14.6 % of the total participants were found to be 
hypertensive (BP >140/90mmHg) and 5.5% were diabetic. The average BMI of the cohort 




2.3.3 Outcomes  
The association between pre-HTN and AF was reported by five prospective studies (49, 118-
121). Adjusted for conventional CV risk factors, pre-HTN increased the risk of incident AF 
by 27% [Figure 2.8.3: HR 1.27 (95% CI 1.14-1.41), p<0.0001]. The population of the included 
studies were comparable with I2 of 38%, p=0.08. The individuals with pre-HTN were older 
with a relatively increased burden of metabolic risks including a higher incidence of 
dyslipidaemia, as compared to normotensive cohort (Table 2.9.3). The overall burden of 
pre-HTN increased by three-fold during the follow up. Further, one-third of participants 
with pre-HTN developed HTN (BP of >140/90 mmHg) during the follow up. Because of the 
variable burden of the cardiovascular risks and diverse methodologies adapted by the 
selected studies for meta-analysis, the reported incidence range of AF was 2.43 to 18 
events/1000 person-years.  
 
2.4 DISCUSSIONS 
This systematic review and meta-analysis present a pooled analysis of prospective 
longitudinal studies associating pre-HTN with incident AF. Pre-HTN as an independent 
predictor was associated with an adjusted 27% increased risk of new-onset AF.  
Hypertension is identified as the most prevalent risk leading to AF (70, 122). A number of 
risk models have incorporated HTN as their integral component to predict AF incidence 
based on a single time point evaluation (123-128).  
Our meta-analysis presents the adjusted risk posed by pre-HTN for the development of 
new-onset AF. Individuals with pre-HTN are likely to develop sustained HTN associated 
with electro-anatomical remodelling of left atrium and a greater risk of future AF.  




conduit arterial stiffness due to sustained central high BP along with endothelial 
dysfunction resulting in left atrial remodelling could be a plausible patho-physiological 
link (16, 35, 37, 39, 129). Aortic stiffness is recognised as a surrogate for central high 
blood pressure and studies have revealed a 30% incidence of increased aortic stiffness in 
middle age cohorts categorised as pre-HTN by brachial BP recordings (129). Aortic 
stiffness assessment by pulse pressure evaluation can provide incremental risk estimation 
concerning new-onset AF, independent of brachial BP values (79, 118).  
Another important observation of our meta-analysis was that the patients with pre-HTN 
had a relative co-existence of cardiovascular risks. This indicates that patients with pre-HTN 
require more extensive cardiovascular profiling to recognise sub-clinical end organ injury. 
Conventionally, HTN induced end organ injury is characterised by diastolic LV assessment, 
retinal examination, urinary albumin: creatinine ratio and LA volume assessment. However, 
incorporation of central blood pressure indices and aortic stiffness appraisal (including 
their response to exercise) can be of incremental value to un-mask early CV remodelling 
with prompt introduction of preventative strategies potentially leading to improve CV 
outcomes. As a modifiable factor, pre-HTN associated with other risks can result in 
structural left atrial changes and increases the risk of new-onset atrial fibrillation.   
The current guidelines do not specify blood pressure targets for AF patients. The SMAC AF 
study recorded no significant difference concerning short term AF free survival in patients 
offered aggressive BP control post ablation (46). However, recent work on aggressive risk 
factor modification has shown superior rates of sinus rhythm maintenance with strict blood 
pressure control (target of <130/80mmHg) along with weight loss in overweight individuals 
with AF (26, 101, 130). This reflects the importance of a holistic approach to modify 




early sub-clinical phase of cardiovascular remodelling in individuals at increased risk of 
hypertension-induced end organ injury. Further studies are required to quantify how 
intensive risk profiling and aggressively targeting pre-HTN can improve AF outcomes.   
 
2.5 CLINICAL IMPLICATIONS 
Our review and meta-analysis have significant clinical implications. Despite being 
recognised as the most common modifiable CV risk in AF, BP targets to prevent the 
arrhythmia are not fully defined. Importantly, individuals with pre-HTN can have central 
arterial stiffness as a possible mechanistic link associating HTN with AF.  
Ongoing aggressive CV risk factor modification in individuals with pre-HTN can provide us 
with a window of opportunity to prevent accelerated CV and left atrial remodelling, 
resulting in reduced AF burden. Further trials identifying pre-HTN patients with a focus on 
defining treatment targets in at-risk individuals will strengthen both primary and secondary 
prevention strategies in AF.  
 
2.6 STUDY LIMITATIONS 
Our review has the following limitations. Due to the nature of the included studies, we 
could only perform an aggregated data analysis of range of cut-offs used to define pre-HTN. 
Most of the included studies characterise the incidence of pre-hypertension and HTN based 
on single point evaluation during follow-up. Additionally, an exhaustive conventional 
cardiovascular risk adjustment was not performed in all the studies selected for analysis as 
listed in Table 2.9.1. However, the incidence of AF is likely to be under-estimated as the 
diagnosis was based on symptoms or pre-defined time points for screening during follow 




and AF outcomes. Arrhythmia burden was not quantified by the included studies nor was 
it further differentiated into AF or atrial flutter. Finally, the cohort selected for analysis 
predominantly consisted of middle-aged Caucasians. It remains unclear whether the meta-
analysis results can be generalized for younger, elderly or non-Caucasian individuals.   
 
2.7 CONCLUSIONS 
Pre-hypertension is found to be independently associated with new-onset AF.  Further 
trials are required for better understanding of this association and defining the role of 
targeting pre-HTN as a part of an aggressive CV risk factor modification programme for the 










Figure 2.8.1: Funnel Plot Showing Publication Bias 
 
 
Rank Correlation Test for Funnel Plot Asymmetry  
Kendall's tau = 0.8000, p = 0.0833 
Egger’s Regression Test for Funnel Plot Asymmetry  
Model: mixed-effects meta-regression model 



























Search Engine: EMbase and PUBMED for English literature until 31st August 2019. Search 
terms “pre-hypertension” or “elevated blood pressure” or “blood pressure” AND 





15530 Records identified by search  
9968 EMBASE 
5502 MEDLINE 




 5116 Duplicate references 
10414 Records screened for 
abstracts and titles 
10390 Studies were excluded after 
title and abstract review  
9931 Outcomes of interest were 
not reported  
399 Replicated publications 
60 Review Articles 
 
24 Full-text articles assessed for 
eligibility 
19 Studies excluded after full-text 
review 
9 Outcomes of interest were not 
reported 
9 Review Articles 
1 Retrospective design  
 
























Table 2.9.1: Overall Characteristics of the Study Participants 
 
(BMI= basal metabolic index, BP= blood pressure, CVD= cardio-vascular disease, CVE= cardio-vascular 
events, DBP= diastolic blood pressure, DM= diabetes mellitus, HDL= high density lipoproteins, h/o= history 
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Table 2.9.2: Quality Assessment of Studies Included in Meta-analysis by 























Valérie Tikhonoff et al. 
Heart 2018 (131) 
* * * * * * * 7 
 
Emdin Connor et al. Int J 
Epidemiol 2017 (54) 
* * * * * * * 7 
 
Wesley O’Neal et al.  J Am 
Soc Hypertens 2015(10) 
* * * * * * * 7 
 
Irene Grundvold et al. 
Hypertension-AHA 2012 
(53) 
* * * *  * * 6 
 
David Conen et al.  
Circulation 2009 (52) 





Table 2.9.3: Characteristics of the Study Participants as per their BP Classification 
(*= statistically significant comparison p-value (p<0.05), BMI= basal metabolic index, BP= blood pressure, DM= diabetes mellitus, HTN= hypertension, Pre-H= pre-hypertension, PP= pulse 







Association of Increased Aortic Stiffness with New Onset 




3.1  INTRODUCTION 
A number of studies have alluded to the predictive value of central arterial stiffness on 
adverse cardiovascular outcomes and increased mortality (132, 133). Likewise, the 
evidence base on the association between aortic stiffness and atrial fibrillation (AF) is on 
the rise (61, 134). Specifically, aortic stiffness as determined by pulse pressure has been 
shown to be associated with increased risk of developing AF independent of established 
cardiovascular risk factors and mean arterial blood pressure in a large population-based 
cohort (118).  
Ageing and hypertension (HTN) are the predominant factors leading to aortic stiffness. In 
addition, the co-existence of HTN with uncontrolled conventional cardiovascular risks 
result in premature conduit vascular remodelling and aortic stiffness (129). Importantly, 
epidemiological studies have revealed that up to 15-20% of middle-aged adults can have 
“sub-clinical” central arterial stiffness (135) as the central high blood pressure is not timely 
diagnosed, in these individuals especially with normal  brachial blood pressure 





Although several non-invasive methods are currently available for evaluation of aortic 
stiffness by employing central pulse wave morphology or velocity assessment (136) its 
integration in routine clinical care and cardiovascular risk profiling remains poor. This may 
be due to the lack of established reference values and standardised measurement 
methodology.  
Furthermore, several studies have reported high pulse pressure (PP) as a marker of aortic 
stiffness and associated it with poor cardiovascular outcomes including new-onset AF (118, 
119). However, aortic pulse wave velocity (PWV) represents the “gold standard” method 
in aortic stiffness assessment with a cut off value of 10 m/s, due to the evidence base 
associating escalated aortic PWV with cardio-vascular and mortality outcomes (137). 
Interestingly, compared to increased PP, the independent association of amplified aortic 
PWV with new onset AF has not been recognised after adjusting for age and HTN (121).  
With the increasing evidence base on the link between aortic stiffness and cardiovascular 
events including AF, we sought to perform a systematic review and meta-analysis to 
determine the strength of these associations in relation to development of new-onset AF 
along with cardiovascular and all-cause mortality. PRISMA guidelines were followed to 
perform literature search and report the results.  
 
3.2 METHODS 
3.2.1  Literature Search 
The meta-analysis was registered with PROSPERO (CRD42018102267). With the help of an 
experienced librarian, an online search of PubMed and EMBASE databases was performed 





distensibility,” “aortic stiffness,” “arterial compliance” or “central blood pressure”, “pulse 
pressure”, “pulse wave velocity,” AND “events”, “atrial fibrillation”, “mortality”, 
“cardiovascular mortality” “outcome”. Duplicate citations were removed.  
3.2.2 Inclusion and Exclusion Criteria 
Prospective longitudinal studies with more than 50 participants and a minimum follow-up 
duration of 1 year that employed standardised methodology to assess aortic PWV, 
ascending aorta distensibility (AAD) or pulse pressure (PP) to quantify aortic compliance 
and its association with all-cause or cardiovascular mortality or new-onset AF were 
included. We included studies published in English language only. In addition, a manual 
search of the bibliographies of the retrieved articles was performed to identify all relevant 
studies.  
We excluded reviews, editorials, case reports, letters and conference abstracts in addition 
to the studies that employed non-standardised methods to measure aortic stiffness and 
those that did not adjust cardiovascular outcomes with blood pressure levels. However, 
their reference lists were manually searched for relevant publications.  
3.3.3 Methods of Aortic Stiffness Assessment in Included Studies 
The aortic stiffness in the selected studies was characterised by aortic PWV, AAD or PP 
evaluation. PP is recorded as the difference between systolic and diastolic blood pressure. 
In contrast, the aortic PWV is determined by the distance covered by the central pressure 
wave between two discrete vascular points and dividing it by the transit time. The AAD is 
derived by comparing the maximum and minimal aortic cross-sectional area determined 





Majority of the studies included in our meta-analysis employed aortic PWV to evaluate 
aortic stiffness by using the following technology: Doppler ultrasound, applanation 
tonometry or oscillometric analysis of pulsatile pressure wave along the vascular wall 
usually at the level of carotid and femoral arteries (118, 133, 138-155). In addition, five 
studies (49, 118-121) examined the association of PP with incidental AF and two citations 
used AAD as a marker of increased aortic stiffness (83, 156).  
3.3.4 Data Extrapolation 
The literature search, study selection and extraction of the data set was performed by two 
authors (KBK and AT) independently. The quality of the studies was gauged by modified 
Newcastle-Ottawa scale by two independent reviewers (KBK and AT) as listed in Table 
3.10.1. Divergent views were resolved by consensus. Data was collected on cardiovascular 
risk profiling of the participants, follow-up duration, methodology used to assess aortic 
stiffness and cardiovascular outcomes. Aortic PWV was generally reported as a categorical 
or continuous variable. Reported quantitative risk estimation for cardiovascular outcomes 
was used for statistical analysis to derive a cumulative hazard profile for each aortic 
stiffness index.  
3.3.5 Statistical Analysis 
Our search resulted in a list of studies with heterogeneous populations and widely 
distributed aortic PWV range. Adjusted odds ratio (OR) or hazard ratios (HR) were used to 
report risk comparison in the studies. To address the widely described range of aortic 
stiffness indices in the included studies, reported data of low and high PWV group for each 
study was extracted to calculate pooled OR and 95% confidence intervals by random effects 





value of p<0.05 was considered statistically significant. Funnel plots were used to examine 
the heterogeneity in reported estimates and publication bias by illustrating effect size 
against standard error (Figures 3.9.1-3.9.7). Furthermore, heterogeneity across studies was 
assessed by using I2 statistic. In addition, where risk was reported per unit of PWV, OR were 
manually adjusted to estimate the risk associated with a 1m/s increase in PWV. Meta-
analysis of studies evaluating aortic PWV was performed to report the pooled OR for 
cardiovascular and all-cause mortality separately. In addition, cumulative OR was derived 
to illustrate the association of high pulse pressure with new onset of AF.  
The terms “predictors” and “impact” are used to describe the association of baseline aortic 
stiffness with defined outcomes including new-onset AF during follow up of selected 
longitudinal studies.  
 
3.4   RESULTS 
3.4.1 Literature Search and Study Selection 
Initial online search of PubMed and EMBASE database retrieved 3,583 studies, which were 
narrowed down to 37 relevant articles as per eligibility criteria (Figure 3.9.8). A further 10 
studies were excluded because of cross-sectional study design, use of non-standardised 
methodology to evaluate aortic stiffness and non-reporting of relevant outcomes. One 
study reporting pulse pressure and new onset AF using 24-hr ambulatory BP monitoring 
was excluded because of its retrospective design (157). Another study was excluded due to 
statistical limitations as it did not report association of pulse pressure with new onset AF 
(158). This meta-analysis included 25 studies: Twenty of these reported on the association 





longitudinal studies explored the association between aortic stiffness and new onset AF 
(49, 118-120, 149). 
3.4.2 Study Population 
3.4.2.1 Aortic stiffness and mortality  
The 20 studies that reported on the association between aortic stiffness and mortality 
recruited 26,614 participants (54% male) with a mean age of 6010 years over a median 
follow-up duration of 7.8 years (Interquartile Range [IQR] 3.3-12.2 yrs.). Though majority 
of the included studies were community based, distinct populations including diabetes, end 
stage renal failure (ESRF) and HTN were represented by two (141, 159), five (138, 140, 
150, 151, 155) and three studies (139, 152, 162) respectively (See Table 3.10.2). Forty 
percent of the total participants were found to be hypertensive with a mean systolic blood 
pressure (SBP) of 14311 mmHg and 23% were diabetic. The average BMI of the cohort 
was 25 kg/m2 and 12% were active smokers. A significant difference in average brachial 
BP between general and HTN participants (135.5 +/- 6 vs 143 +/- 7, p= 0.04) was 
recorded.  
The mean PWV of the cohort was 10.81.8 m/s with no significant differences seen 
between the general, hypertensive, diabetic or ESRF populations (10.81.8, 10.91.8, 
11.1±2.6 or 10.41.2 m/s respectively; p=NS).  
3.4.2.2 Aortic stiffness and atrial fibrillation 
The five longitudinal studies that described the association of aortic stiffness with new-
onset AF have 26,868 participants with a mean age of 624 years (48% male) and a mean 





analysis were community based (118, 119, 121). Discrete population of hypertensive and 
diabetic participants were represented by one study each (49, 120). Although 46.5% of the 
participants included in the pooled analysis were known to have HTN, the mean BP for the 
cohort was 128  14mmHg.  The average BMI of the participants was 27.6±1.4 kg/m2 with 
28% incidence of diabetes (See Table 3.10.3). The mean pulse pressure for the selected 
cohort was 60±16 mmHg with a mean HR of 666 bpm.  
3.4.3 Outcomes  
3.4.4 Cardiovascular mortality  
The association between aortic stiffness and CV mortality was reported by 19 studies (83, 
133, 138-140, 143-147, 150-155, 159-161). Twelve of these studies (138-140, 143, 146, 148, 
150-152, 154, 159, 160) including a sub-study (148) reported PWV as a continuous variable 
while seven reported it as categorical (83, 133, 144-147, 155). Three studies reported PWV 
as both categorical and continuous variable concomitantly (138, 143, 153).  Every metre 
per second (m/s) increase in PWV was associated with an independent 25% increase in CV 
mortality [Figure 3.9.9: OR 1.25 (95% CI: 1.16-1.34), p<0.00001]. An adjusted pooled high 
PWV (>10.7 ± 0.5 m/s) was associated with more than two-fold increase in CV mortality 
[Figure 3.9.10: OR 2.34 (95% CI 1.81-3.02), p=0.0001]. Moderate to high heterogeneity was 
seen in the studies that reported PWV as categorical (I2=41%, p=0.00001) or continuous 
variable (I2=78%, p<0.00001) in association with CV mortality.  
3.4.5 All-cause mortality 
All-cause mortality was reported by 10 studies (83, 141-144, 147, 148, 152, 155, 160). The 
pooled analysis of five studies (141, 148, 152, 155, 160) revealed a 16% increase in all-cause 





factors including ageing [Figure 3.9.11: OR 1.16 (95% CI: 1.08-1.25), p<0.00001]. On the 
other hand, meta-analysis of six studies (83, 138, 142-144, 147) reported a 57% increased 
risk of all-cause mortality with adjusted high versus low PWV  with a cut off of 10.3±2 m/s 
[Figure 3.9.12: OR 1.57 (95% CI: 1.2-2.1), p=0.0010]. Significant heterogeneity was seen in 
the studies that reported PWV as categorical (I2=57%, p=0.04) or continuous PWV variable 
(I2=88%, p=0.00001) in association with all-cause mortality.  
3.4.6 Pulse pressure and atrial fibrillation (AF) 
The association between pulse pressure (PP) and AF was reported by five prospective 
studies (49, 118-121). Adjusted for conventional CV risk factors, high PP (60 ± 16 mmHg) 
increased the risk of developing new-onset AF by 38% [Figure 3.9.13: OR 1.38 (95% CI 1.15-
1.64), p=0.0004]. Significant heterogeneity was seen amongst these five studies (I2=75%, 
p=0.003). Interestingly, none of the studies reported adjusted aortic PWV as an 
independent predictor of new-onset AF. In addition, the selected studies did not 
differentiate atrial flutter from AF or different AF subtypes. 
 
3.5 DISCUSSIONS 
This systematic review and meta-analysis present a pooled analysis of prospective 
longitudinal studies associating aortic stiffness, defined as elevated PWV (>10.7± 1.7m/s), 
with CV and all-cause mortality. High PWV was associated with an adjusted two-fold and 
57% increased risk of CV and all-cause mortality respectively. Furthermore, each m/s 
increase in PWV was also associated with an adjusted 25% and 16% increased risk of CV 
and all-cause mortality, respectively. Notably, the association between aortic stiffness with 





and specific ESRF, hypertensive and diabetic populations. Furthermore, increased PP was 
found to be an independent predictor of new-onset AF. High PP (>60mmHg) was 
independently associated with an adjusted 38% increased risk of new-onset AF.  
3.5.1 Association of Aortic Stiffness with CV and All-cause Mortality 
The association between increased aortic stiffness and mortality including CV outcomes is 
well described in community-based population studies as well as in diverse groups 
including elderly, ESRF, hypertensive and diabetics (83, 147, 148, 155, 159, 161, 163, 164). 
Importantly, our review further affirmed the independent predictive value of arterial 
stiffness beyond known cardiovascular risk factors including HTN. However, the clinical 
utility of aortic stiffness assessment is inadequate due to the lack of established reference 
values and standardised measurement methodology. Undeniably, numerous methods to 
appraise aortic stiffness by various modalities can add further confusion in the clinical 
settings. Majority of the studies included in our review employed aortic PWV to quantify 
arterial stiffness (Table 3.10.1). However, these studies employed four different non-
invasive devices using oscillometric and applanation tonometry techniques (139, 140, 161). 
Furthermore, five studies (138, 141, 143, 144, 146) included in our analysis used Doppler 
to compute carotid-femoral PWV. Despite validation and reported correlation of different 
techniques and devices (129, 133, 136, 165, 166) disparities were reported during 
calculation of surface distance between carotid and femoral arteries for non-invasive PWV 
assessment (Table 3.10.1). Of note, these commercially available validated devices 
examine different aspect of ascending aortic response to ejected volume load to compute 





are not interchangeable due to the technical limitations posed by device software and 
characteristics of the population studied (136, 166, 167). 
Nevertheless, aerobic exercises and weight loss with ongoing cardiovascular risk factors 
modification in addition to BP control is reported to improve arterial stiffness in 
observational settings (168). Treatment with angiotensin converting enzyme inhibitors 
have been found to improve vascular physiology by refining endothelial function through 
enhanced release of nitric oxide and inhibition of fibrosis on vascular layers, but the actual 
mechanism  influencing the arterial stiffness beyond BP control is yet to be elucidated (169). 
Although, the moderate intensity aerobic exercise has been reported to be modestly 
effective in reducing aortic stiffness,  the underlying mechanisms remain poorly 
understood (170). Further work is needed to evaluate other treatment options useful to 
reduce aortic stiffness that may improve clinical outcomes. 
3.5.2 Aortic Stiffness and AF 
Although the link between aortic stiffness and AF recurrences post cardioversion or 
catheter ablation has been reported previously (61), the current meta-analysis 
demonstrated that high PP (>60mmHg) is independently associated with the development 
of new-onset AF. The mechanisms by which aortic stiffness results in AF remain 
incompletely understood but are thought to involve left atrial stretch in the setting of left 
ventricular diastolic dysfunction that contributes to AF triggers, perpetuators and substrate 
(171).  
3.5.2.1 Association of PWV with new-onset AF  
Except augmented pulse pressure, other methods to characterise aortic stiffness were not 





AAD was not predictive of AF development in the Multi-Ethnic Study of Atherosclerosis 
(MESA) (119). Further, in contrast to central PP and augmentation index, PWV was not 
reported to be independently associated with incidental AF in the Framingham Heart Study 
offspring and third-generation cohorts (119, 149, 172).   
These inconsistencies may in part be explained by the different populations studied and 
methods employed for aortic stiffness assessment. Central PP is defined as the difference 
between central systolic and diastolic blood pressure. It represents central pulsatile load, 
which determines the extent of atrial stretch and potentially influences the onset of AF 
(129, 173). In comparison, the aortic PWV is determined by the distance covered by the 
central pulsatile pressure wave between two distinct vascular points and dividing it by the 
transit time. The propagation velocity of the pressure wave is the major determinants of 
aortic PWV. In comparison to PP, the distal vascular segments significantly affect aortic 
PWV assessment during cross talk of ejected and reflective pulse (167).  
3.5.2.2 Aortic stiffness, pre- HTN and AF  
In general, the non-invasive measures of aortic stiffness indices provide incremental risk 
estimation independent of peripherally derived systolic BP readings. These central 
measures may be more patho-physiologically relevant than peripheral BP given the 
proximity to the heart. Therefore, these indices may be useful for identifying high-risk 
patients including ‘pre-hypertension’ (174) or those with persistent aortic stiffness despite 
optimal blood pressure control (175). However, these observations are not tested in a trail 
settings and further studies are required to explore the utility of “re-classification” of 
participants as per their aortic stiffness indices and the impact of targeting aortic stiffness 





pressure targets in the care of AF patients while recent work on aggressive risk factor 
modification has shown superior rates of sinus rhythm maintenance with strict blood 
pressure control (target of <130/80mmHg) and weight loss in overweight and obese 
individuals with AF (26). However, none of the devices used to quantify aortic stiffness and 
central pressure indices non-invasively, is validated to be used during AF whereby the 
ventricular rates are irregularly irregular and often rapid. More work is needed to delineate 
how additional active monitoring and targeting of aortic stiffness indices can improve 
outcomes in AF patients.   
 
3.6 CLINICAL IMPLICATIONS 
The above observations have strong clinical implications, as aortic stiffness is a modifiable 
risk factor that can be evaluated non-invasively and with relative ease. Importantly, the risk 
associated with aortic stiffness is independent of HTN and other established CV risk factors. 
Further, recent evidence from the Framingham Heart Study illustrated 60% prevalence of 
aortic stiffness in hypertensive individuals with well-controlled blood pressure during 
monitoring. This finding may well  explain the residual risk that requires further attention 
to improve CV outcomes (176). Aortic stiffness can be modified by aggressively targeting 
cardiovascular risk factors including hypertension, obstructive sleep apnea, increased pule 
pressure and obesity (168, 177). Further trials with a focus on methodological 
standardisation of central pressure indices with attention to the impact of reducing aortic 
stiffness on mortality and sinus rhythm maintenance will strengthen the case to assimilate 
central pressure estimation in conventional risk profiling of our patients. Taken together, 





strongly considered in both primary and secondary prevention settings. However, further 
studies are needed to define optimal treatment targets in different sub-population of at-
risk individuals, such as those with AF 
 
3.7 STUDY LIMITATIONS 
Our review has the following limitations. First, due to the nature of the included studies 
with heterogenous population, we could only perform an aggregated data analysis of the 
variable methodology and cut-offs for aortic stiffness indices. Second, the studies included 
in the meta-analysis span over two decades and the management of  cardiovascular risks 
has significantly advanced during that period. We were unable to perform an exhaustive 
adjustment for all the known cardiovascular factors and accepted a pooled analysis 
adjusted for the conventional cardiovascular risks by these selected studies as listed in 
Table 1 and 2. Additionally the CHA2DS2VASC score and the anti-coagulation regime 
instigated during follow up was not reported. Third, this meta-analysis is not able to tease 
out the impact of medications on the measures of aortic stiffness or CV outcomes. Finally, 
the cohort selected for analysis was predominantly consisted of middle-aged and older 
Caucasians. It remains unclear whether the meta-analysis results can be generalized for 
younger or non-Caucasian individuals.   
 
3.8 CONCLUSIONS 
Aortic stiffness as a surrogate for central high blood pressure is independently associated 





profiling by pulse pressure assessment can be of additional value in predicting new-onset 
AF. Further studies are required to explore this association of aortic stiffness to improve AF 

































Figure 3.9.1: Funnel Plot Illustrating Heterogeneity Amongst the Studies 

















Figure 3.9.2: Funnel Plot Illustrating Heterogeneity Amongst the Studies 











Figure 3.9.3: Funnel Plot Illustrating Heterogeneity Amongst the Studies 






















Figure 3.9.4: Funnel Plot Illustrating Heterogeneity Amongst the Studies 






















Figure 3.9.5: Funnel Plot illustrating Heterogeneity Amongst the Studies 

















Figure 3.9.6: Funnel Plot Illustrating Heterogeneity Amongst the Studies 



















Figure 3.9.7: Funnel Plot Illustrating Heterogeneity Amongst the Studies 







































































Table 3.10.1: Quality Assessment of Studies Included in Meta-analysis by 
Modified Newcastle-Ottawa Scale 
 
 











Follow up Outcome  
Alban Redheuil, JACC. 2014 Dec 
23;64(24):2619-29. MESA Study 
* * * * * * * ******* 
Anderson et al., HTN 2009 * * * *  * * ****** 
Anne C K Larstop et al HTN 2012, 60; 
347-353. LIFE study. 
* * *  * * * ****** 
Blacher et al., 1999  * * * * * * ****** 
Cruickshank et al., 2002 * * * * * * * ******* 
Gary F. Mitchell, MD. JAMA. 
2007;297:709-715" 
 
* * *  * * * ****** 
Laurent et al., 2001 * * * * * * * ******* 
Mattace-Raso et al., 2006 * * *  * * * ****** 
Meaume et al., 2001 * * * * * * * ******* 
Nicholas S Roetker Am J Cardiol 
2014;114:587-592 
* * *  * * * ****** 
Noriko Inoue etal. Circ J 2009; 73: 549  
–  553 
 
* * * * * * * ******* 
Pannier et al., 2005  * *  * * * ***** 
Roman et al. JACC 2009 Oct 27; 
54(18): 1730–1734. The Strong Heart 
Study 
* * *  * * * ****** 
Shaikh etal. Hypertension 
2016 ;68:590-596 
* * * * * * * ******* 
Shoji et al., 2001  * * * * * * ****** 
Shokawa et al., 2005 * * *  * * * ****** 
Stephane Laurent et al. Stroke. 
2003;34:1203-1206 
* * *  * * * ****** 
Sutton-Tyrrell et al., 2005 * * * * * * * ******* 
Terai et al., 2008 * * * * * * * ****** 
Valbusa F, etal. Diabetes Care. 2012; 
35:2337–2339. 
* * *  * * * ****** 
Verbeke etal. CORD study. AJN, vol. 6, 
2011 
 * *  * * * ***** 
Wang et al., 2010 * * *   * * ***** 
Wijkman M etal. J Diabetes 
Complications. 2016 Sep-
Oct;30(7):1223-8 
* * *  * * * ****** 
Willum-Hansen et al., 2006 * * * * * * * ******* 

















AA= abdominal aorta, BMI= body mass index, CCA= common carotid artery, CMR= cardiac MRI, CVD= cardiovascular 
disease, CRP= C- reactive protein, DM=diabetes mellitus, eGFR= estimated glomerular filtration rate, FA= femoral 
artery, Hb= haemoglobin, HbA1c= glycated haemoglobin, HDL= high density lipoprotein, HR= heart rate, HTN= 
hypertension, IGT=impaired glucose tolerance, IMT= intima- media thickness, MBP= mean BP, LVH= left ventricle 
hypertrophy, M=male, F=female, m/s = metre/second, NA= not applicable, NR = not reported, PP= pulse pressure, PTH= 
serum parathormone, SBP= systolic BP, SCN= sterno-clavicular notch. 
 
 
















































































































































































































































































BMI= basal metabolic index, CVD= cardiovascular disease, DM=diabetes mellitus, FRS= Framingham risk score, HTN= 










Non-Invasive Central Blood Pressure and Aortic Stiffness 
Indices Estimation and Technical Challenges 
 
4.1  INTRODUCTION 
Hypertension (HTN) is strongly associated with adverse cardiovascular (CV) outcomes and 
atrial fibrillation (AF) (14, 61). Despite the epidemiological studies associating pre-HTN 
with AF, uncertainties exist concerning intensive control of blood pressure in primary and 
secondary prevention of AF(46). The management of hypertension is driven by brachial 
blood pressure evaluation despite superior predictive relevance of aortic stiffness and 
central pulsatile load estimation (83, 178). Epidemiological data has suggested a 70% 
incidence of grade I central high blood pressure in individuals categorised as pre- 
hypertensive (120-139/80-89 mmHg) according to their brachial blood pressure 
assessment (80). Central blood pressure estimation can better characterise the pre-HTN 
group concerning risk of developing end organ injury and AF. However, the clinical 
applicability of central blood pressure (CBP) assessment is still limited as the methods of 
evaluation remain to be standardised and evidence targeting CBP to improve 
cardiovascular outcome is still evolving (80).  
Majority of commercially available devices acquire central blood  pressure waveform by 
calibrating peripheral blood pressure wave through applanation tonometry or automated 





available non-invasive devices is considered “acceptable” with a mean difference of 5±8 
mmHg, during comparative analysis with invasive ascending aortic pressure (180). 
However, some of these published studies lacked statistical power concerning validation, 
with a variable range of correlation and agreement values (181, 182). Further, application 
of various methodologies to estimate CBP indices resulted in inconsistent reporting of  
their predictive value independent to brachial BP (164, 183).     
This review is aimed to critically appraise the methodology adopted by the commercially 
available devices to compute CBP and aortic stiffness. Delineating the strength and 
limitation of these devices will guide further application and validation of their use in AF 
patients.   
4.2  CBP ASSESSMENT METHODS  
In general, non-invasive CBP assessment is based on the indirect assessment of aortic 
compliance through estimation of central pulsatile load and waveforms. Overall, a 
10mmHg amplification of pressure wave is recorded at the brachial arterial site compared 
to ascending aortic pressure (184). A number of non-invasive devices derive central 
pressure waveform by acquiring peripheral pressure wave that is further calibrated to the 
brachial BP. This calibrated peripheral pressure waveform is then used to form a central 
pressure wave through application of mathematical transfer function and wave analysis 
(Table 4.9.1). Invasive studies have validated these mathematical models used in non-
invasive assessment of CBP with acceptable range of accuracy during sinus rhythm (185). 
However, standardisation of the available techniques to derive central pressure 





outcome studies employing a range of devices to estimate CBP indices in a 
heterogeneous population may have limited the potential additional value of CBP 
assessment over traditional brachial BP readings (186). In addition, none of these non-
invasive devices are validated to estimate CBP during AF.  
4.2.1 Methods of Peripheral Pressure Wave Recording 
In order to acquire CBP waveform, the non-invasive devices record peripheral pressure 
wave through applanation tonometry or by pulse volume plethysmography (PVP).  
4.2.1.1 Applanation Tonometry  
Applanation tonometry is one of the most common technique used by the non-invasive 
devices to acquire peripheral arterial pressure waveform as shown in Table 4.9.1. It is 
based on the principle that the external pressure applied to completely compress the 
artery is equal to the internal pressure, provided the applanation sensor is stable and 
completely in contact with the vascular wall. The pressure sensor used to applanate the 
artery can be single or arrayed. The pressure waveform acquisition by single sensor probe 
is operator dependent as one have to adjust the manual pressure application to acquire 
optimum pressure waveform. To ensure quality control, an inter-operator and intra- 
operator variability must be recorded for single sensor transducer.  In comparison, an 
arrayed sensor is relatively operator independent and adjust its pressure application and 
acquisition of pressure wave automatically. Applanation of a superficial peripheral arterial 
segment is found to be more effective where the vascular wall is relatively fixed over a 
bone with stable sensor position during the cardiac cycle.  The radial artery satisfies all 





demanding because of the presence of soft tissue and risk of atherosclerotic plaque 
rupture along with relative mobility of surrounding structures during respiration (179).  
4.2.1.2 Pulse Volume Plethysmography (PVP) 
Pulse volume plethysmography (PVP) is another method to acquire peripheral pressure 
waveform by estimating the volume shift at brachial arterial site evaluated by a pressure 
cuff equipped with a specialised sensor at the time of brachial BP assessment. A number 
of devices are commercially available to perform CBP assessment by acquiring pulse 
volume through peripheral oscillometric cuff as listed in Table 4.9.1. In general, these 
devices record volume shift at peripheral arterial site and conform a peripheral pressure 
waveform (187, 188). This recorded pressure waveform is then calibrated as per acquired 
brachial BP. This calibrated waveform is then utilised to acquire central pressure wave to 
estimate CBP and its indices. Some of these devices using PVP to estimate CBP indices 
offer ambulatory CBP estimation because of their automated design. However, not all of 
these devices are validated against invasive CBP assessment and hence not an ideal 
screening tool to perform ambulatory CBP (189). In addition, the use of these devices is 
not validated during AF because of significant variation in heart rate (HR) resulting in 
erratic peripheral pressure wave amplitude. 
4.2.2 Calibration of Peripheral Pressure Waveform  
The non-invasive estimation of CBP requires accurate calibration of the peripheral 
pressure waveform. The assumption of a relatively stable diastolic and mean blood 
pressure throughout the circulation provides the basis to use these indices for calibration 





systolic, diastolic and mean BP, derived from an automated cuff based device are used to 
calibrate peripheral pressure wave (179).  Calibration algorithms can be different, 
depending on the peripheral site of assessment to compensate for the peripheral 
amplification of the pressure wave. In case of carotid artery tonometry, the pressure 
waveform is calibrated to brachial mean and diastolic pressure (179).  In contrast, 
peripheral pressure waveform acquired by radial artery tonometry is calibrated to 
brachial systolic and diastolic blood pressure as from a practical point of view, there is no 
significant pressure amplification between the two sites.  
In addition to tonometry, a new generation of automated cuff based devices are 
acquiring peripheral pressure waveform at brachial site by estimation of the volume 
displacement over time and further auto-calibrating it to the mean, systolic or diastolic 
brachial BP by applying principles of pulse volume plethysmography (PVP) (190).  
However, we know that peripheral amplification of systolic and mean BP (MBP) can be 
inconsistent depending on HR variability. Further, cuff based non-invasive assessment of 
brachial BP is not entirely accurate (180). The calibration errors introduced by the 
variable brachial BP indices are recognised as a major source of inaccuracy (191). Non-
invasive CBP estimation during AF can be inaccurate by adapting current techniques 
because of their dependence on heart rate and peripheral blood pressure to calibrate 
pressure waveforms before subjecting it to mathematical algorithms to compute CBP and 





4.2.3 CBP Estimation Algorithms 
4.2.3.1 Generalized transfer function (GTF)  
The transfer function is a mathematical algorithm to depict the relation between the 
input (peripheral pressure wave) and output (central pressure wave) signals in a 
frequency domain. There are no significant differences between the pressure pulse 
transduction properties of aorta and upper limb peripheral arterial tree concerning lower 
frequency. These lower frequencies (3 Hertz) constitutes 90% of the aortic pressure 
waveform. The GTF is essentially a low-pass frequency filter applied to the calibrated 
peripheral arterial pressure waveform acquired during inflation of the brachial cuff to 
constitute aortic pressure wave. (179, 188, 191) The acquired central pressure waveform 
is then subsequently used to calculate CBP and its indices (Figure 4.8.1).  The GTF showed 
strong correlation with invasive CBP assessment, as a result, it was one of the first 
methodology approved by (Food and Drug Administration (FDA) to estimate CBP with 
multiple clinical validation publications (181, 192, 193). However, GTF has certain 
limitations including reduced precision in assessment of CBP indices requiring high 
frequency components like augmentation index (AI) (179). Additionally, input errors due 
to erratic HR during AF and erroneous brachial pressure readings can lead to inaccurate 
CBP assessment.  
4.2.3.2 CBP assessment based on the second systolic pressure peak (SBP2) 
This cuff based CBP estimation method is clinically more convenient. It is based on the 
observation that the second systolic pressure peak (SBP-2, Figure 4.8.1) at the peripheral 





gradient in arterial tree during late systole is relatively small and it mainly comprises of 
low frequency components. Additionally, the reflective component of CBP wave (P2) is 
the dominant systolic peak recorded in an adult population. The CBP assessment based 
on peripheral pressure systolic peaks can be performed non-invasively. However, its 
reliance on peak of reflective pressure wave (P2) limits its use during AF and in elderly 
patients with advanced vascular remodelling because of the significant variability in wave 
amplitude (179).  
4.2.3.3 CBP assessment based on physics model 
This technique calculates CBP indices by estimating the pressure fluctuations recorded by 
sphygmomanometer cuff applied at the brachial arterial site. As a first step, the device 
determines brachial BP indices by sphygmomanometer cuff. The device then re-inflates 
the cuff to hold the pressure at 30mmHg above the estimated brachial systolic BP for >10 
seconds to record the small intra-arterial pressure fluctuations. These recorded small 
pressure fluctuation at brachial artery are used to estimate aortic pressure by application 
of a physics model. The model estimates pressure wave reflection between the open 
(aortic) and closed (brachial) end in a time domain by assuming a uniform tube model 
between the two vascular sites. This technique is validated and mainly used by Pulsecor R 
6.5 (Pulsecor Ltd. Auckland, New Zealand) to estimate CBP indices (194). The physics-
based model is of limited value in patients with peripheral vascular disease involving sub-
clavian artery. In addition, precise calibration of central aortic pressure waveform through 
this technique is also dependent on accurate brachial BP assessment.  





NPMA is a mathematical low pass filter applied to the acquired radial or brachial pressure 
waveform to exclude high frequency signals and estimate peak of  central aortic pressure 
waveform (195). Here “N” represents acquisition of sampling frequency. Each frequency 
signal point is summed up with its neighbours and divided by the number of data points. 
The pressure wave uniformity improves with the increase in number of data points. 
Therefore, the common denominator of the filter is imperative and strongly related to 
sample frequency. In general, the NPMA method with a common denominator of 4 (a 
quarter of the acquired sampling frequency= N/4) is reported to record the CBP with 
relative accuracy (195). However, the NPMA is dependent on peripheral pressure wave 
calibration. Further,  accurate range of optimal frequency denominator can vary from N/4 
to N/6 (179). Despite illustrating a strong correlation with invasive CBP assessment, 
NPMA based non-invasive central pressure valuation under-estimates central systolic BP 
by a mean of 7.6mmHg (195). Moreover, acquisition of central pressure waveform is not 
possible through this method, further limiting its clinical utility as a  screening tool in CBP 
assessment (179).  
4.2.3.5 Direct Method to Assess CBP waveform  
This technique uses carotid artery applanation tonometry to record the central pressure 
waveform. Both PulsePen (Dia Tecne, Milan, Italy) and Compilor Analyse (ALAM Medical, 
Vincennes, France) are validated devices that record central pressure waveform at carotid 
arterial site with relative accuracy (196, 197). One of the major limitations is that the 





arterial and diastolic pressure values obtained by conventional sphygmomanometer 
application at brachial artery.    
4.2.4  ACCURACY OF AVAILABLE DEVICES TO ESTIMATE CBP NON-
INVASIVELY  
To date, there is no perfect method to estimate CBP non-invasively. A considerable 
variation is reported concerning the methodology, accuracy and validation of different 
devices used to estimate central pressure waveform and CBP indices (82, 129, 166, 179, 
180, 189, 191, 198-200). Several limitations need to be addressed to improve precision in 
acquisition of central pressure waveform and calculation of CBP indices to better 
incorporate CBP assessment in clinical practice. 
As compared to invasive central systolic BP, the commercially available devices under-
estimate the systolic CBP by a mean of 5 mmHg (Table 4.9.1).  In general, non-invasive 
devices over-estimate central diastolic BP (CDBP). As compared to invasive aortic 
pressure assessment, Sphygmocor XCEL was reported to over-estimate CDBP by a mean 
of 13 ± 6 mmHg with under-estimation of pulse pressure by a mean of 18 ± 10 mmHg 
(190). There are inherent limitations in the current available techniques to estimate CBP 
indices.  Applanation tonometry has been around the longest and hence has more 
evidence base as compared to cuff-based sphygmomanometer (189, 201, 202) in recording 
peripheral pressure waveform as shown in (Table 4.9.1). These approaches are not equal 
in their estimates of peripheral pressure waveforms. The non-invasive devices used cuff 





indices. Because of the inconsistencies in brachial BP evaluation, this step was found to 
be the major source of introducing error in CBP wave formation to derive CBP indices 
(203).  
As a first step, a standardised and a relatively operator independent cuff base 
methodology has to be adopted to improve CBP indices assessment. At times, the new 
CBP assessment devices are validated against established non-invasive CBP evaluation 
techniques to confirm their accuracy and reliability. However, the majority of these 
evidence base and old non-invasive CBP assessment devices use brachial BP indices to 
calibrate peripheral pressure waveform and have the same inherent limitations as 
discussed above. Further, these methodologies are highly sensitive to heart rate 
variability and peripheral pressure wave amplitude, limiting their utility to appraise CBP 
during AF. For validation, adequately powered studies with invasive operator 
independent measures and strict quality control criteria for acquiring and calibrating 
peripheral pressure waveform can help reduce the inconsistencies reported by various 
devices during CBP indices assessment.   
4.3  AORTIC STIFFNESS AND ITS ASSESSMENT 
A compliant aorta is a conduit that acts as a buffer to LV ejection pressure and help 
maintain a steady flow to the end organs during diastole. Ageing and HTN are the major 
risks related to premature aortic stiffness. Aortic stiffness is recognized as a surrogate for 
persistently high CBP. Non-invasive assessment of aortic stiffness is performed by aortic 
pulse wave velocity (aPWV) appraisal, central pulsatile load recording or ascending aortic 





central pulsatile pressure and volume load during ventricular-arterial coupling. As the 
conduit artery remodels, the aPWV increased with amplification of pulse pressure and 
reduced distensibility of proximal aorta (83). However, aortic PWV is accepted as a 
standard method to quantify aortic stiffness because of the published evidence base and 
its reproducibility (146-148, 155, 164).  A variety of devices can be employed to estimate 
aortic pulse wave velocity (aPWV) to calculate aortic stiffness, non-invasively (82). Aortic 
PWV is calculated from the distance travelled by the pulsatile wave between two vascular 
sites and dividing it by transit time. The carotid and femoral arteries are the most 
common vascular points used to determine aPWV and is recognized as a “gold standard” 
to calculate the aortic stiffness (Figure 4.8.2) (30).  The association between increased 
aortic stiffness and CV as well as all-cause mortality is well described.  (133, 144, 155, 159, 
161) as shown in Table 4.9.2. Central aortic compliance can also be estimated by central 
pulse pressure (CPP) and augmentation index (CAIx) calculation. CAIx is derived as a ratio 
between central augmentation pressure and central pulse pressure (CAIx=CAP/CPP x100). 
Increased pulse pressure (>60mmHg) with reduce diastolic BP (<70mmHg) is a strong 
indicator of conduit vascular remodelling (178). Increased pulse pressure (PP) is found to 
be independently associated with increased CV events including incidence of AF (61). 
However, evidence correlating increased CAIx with hard CV outcomes is limited (199).  
Carotid-Ankle pulse wave index (CAVI) is a recent addition in the available techniques to 
estimate vascular stiffness but its dependence on baseline arterial tone and limited 
applicability  in patients with peripheral vascular disease (Ankle-brachial index <0.9) 
preclude its clinical utility (204). In recent years, cardiac MRI is being used to calculate 





distensibility is calculated by the following equation: Change in aortic area (systole-
diastole)/ PP x minimum aortic area (83, 165). The PP is estimated by deducing diastolic 
brachial pressure from its systolic counterpart, recorded by a cuff-based 
sphygmomanometer conventionally at the time of aortic distensibility assessment. CMR 
can also be used for aortic PWV velocity assessment. Reduced aortic distensibility and 
increased aortic PWV recorded by CMR is found to be significantly associated with 
adverse CV and AF outcomes (83, 119, 205). Despite the reproducible and consistent 
methodology of aortic distensibility assessment by CMR, its cost and relatively limited 
access are significantly limiting its widespread clinical use. However, aortic distensibility 
assessment can reliably performed in sinus rhythm and its validation during AF is yet to 
be reported.  
4.5  CLINICAL RELEVANCE OF CBP INDICES AND AORTIC STIFFNESS 
Aortic stiffness is a modifiable risk factor that can be evaluated non-invasively and with 
relative ease. Importantly, the adverse outcome associated with aortic stiffness is 
independent of HTN and other established CV risk factors. Recent evidence from the 
Framingham Heart Study demonstrated 60% prevalence of aortic stiffness in hypertensive 
individuals with well-controlled blood pressure. CBP assessment is of independent value 
over and above brachial BP in predicting CV events. This finding may well  explain the 
residual risk associated with increased aortic stiffness that requires further attention to 
improve CV outcomes (176). Specifically, CBP appraisal is particularly relevant in the 





4.5.1 Characterising Systolic HTN in the Young 
In younger and healthy individuals, central systolic BP is found to be lower than 
peripheral BP. A peripheral amplification of systolic BP is recorded in approximately 5 % 
of  young males with an overall prevalence of 2.7% (206) . An isolated systolic 
hypertension is incidentally found in these individuals with normal diastolic BP (207). In 
general, HTN work up excludes any underlying secondary cause and these young 
individuals exhibit hypotensive response to treatment. They have normal CBP indices 
including pulse pressure (PP).  In comparison to central pressure, the morphology of 
peripheral pressure waveform demonstrates a relatively increased systolic amplification. 
The isolated systolic peripheral amplification in young (<40 years) is not associated with 
any adverse cardiovascular outcomes. Hence, the CBP assessment in younger individuals 
with amplified brachial BP is strongly advocated to avoid unnecessary therapy and 
anxieties associated with diagnosis of HTN.   
4.5.2 Aortic Stiffness and Pre-HTN  
Ageing and Increased central pulsatile load can lead to premature stiffness of aorta. The 
causality of aortic stiffness and HTN is not fully established. However, studies have 
reported accelerated conduit vascular remodelling preceding diagnosis of HTN (208) . 
Aortic stiffness is one of the possible mechanism associating HTN with end organ injury 
(209). Moreover, amplified pulse pressure as a marker of increased aortic stiffness is 
independently associated with increased incidence of AF (118). Concerning CV outcomes, 
HTN with stiffened aorta incurred a higher prognostic risk as compare to HTN alone. 





addressing vascular risk factors including obesity (169). These findings further support the 
important role of aortic stiffness assessment and its integration in ongoing risk factor 
modification model to improve AF and CV outcomes. Compared to carotid-femoral PWV, 
targeting high CPP and Aix to improve CV morbidity is yet to be reported as these indices 
has to be adjusted for multiple factors including ageing, gender, heart rate, height and 
blood pressure (129, 169).  
4.5.3 Ageing Related Arterial Stiffness and Cardiovascular Events 
Ageing transforms conduit arterial compliance resulting in aortic stiffness. A stiffened aorta 
transfers its pulsatile load to the vital end organs without applying any buffering. In 
response to that, the resistance arterioles transform into an elastic reservoir resulting in 
reduced augmentation and diastolic BP with overall labile BP recordings. Uncontrolled 
cardio-vascular risks accelerate this physiological process of vascular ageing leading to 
premature conduit vascular remodelling, eventually resulting in irreversible end organ 
injury. In general, a steady rise in systolic BP is recorded from the age of 45 years onwards. 
In contrast, the diastolic BP remains stable resulting in escalated pulse pressure (PP= 
systolic - diastolic BP). Hence, increased PP is associated with increased aortic stiffness and 
reported to be an independent predictor of CV and AF outcomes particularly in individuals 
with age range of 40-60 years (61, 164). An independent association between increased 
aortic stiffness, recorded as amplified carotid-femoral PWV, and mortality (including CV 
mortality) is well described in community-based population studies as well as in those with 
end stage renal disease and diabetes mellitus (83, 147, 148, 155, 159, 161, 163, 164). The 





studies (169, 210, 211). Treatment with angiotensin converting enzyme inhibitors can 
improve vascular physiology by enhancing endothelial function through enhanced release 
of nitric oxide and inhibition of fibrosis on vascular layers, in addition to BP control (169, 
212). In addition, moderate intensity aerobic exercise has been found to be effective in 
reducing aortic stiffness although the underlying mechanisms remain poorly understood 
(170). Despite an independent and modifiable factor, the limited realisation of aortic 
stiffness assessment in ongoing robust CV risk factor management represents an unmet 
therapeutic target and future studies can help address this gap.  
4.6 LIMITATIONS OF CURRENT METHODOLOGIES TO ASSESS AORTIC 
STIFFNESS and CBP INDICES 
A lack of standardised methodology is a major factor limiting the clinical use of CBP 
indices and aortic stiffness assessment. The differing methods used to appraise CBP 
indices and aortic stiffness can add further confusion in the clinical setting. In general, 
majority of the non-invasive devices calibrate pressure waveform by brachial BP indices. 
The variable precision with the techniques adopted to assess brachial BP has been found 
to be the major source of error in central pressure wave assessment (190). Furthermore, 
as compared to brachial BP measurements, the additional time, cost, technical challenges 
and training requirements needed for CBP assessment may hinder its clinical applicability. 
Majority of the studies employed carotid-femoral PWV (cfPWV) to quantify aortic 
stiffness. However, these studies employed four different non-invasive devices using 
Doppler, oscillometric and applanation tonometry techniques (138-141, 143, 144, 146, 





estimate aortic stiffness (129, 133, 136, 165, 166), disparities were also reported during 
calculation of surface distance between carotid and femoral arteries for non-invasive 
cfPWV assessment (129). Of note, the relative dependency of CBP and aortic stiffness 
assessment algorithms on baseline HR and peripheral pressure wave acquisition 
significantly restrict their use during AF. Despite a reported independent association of 
increased aortic stiffness with AF, none of the commercially available device is validated 
to access CBP and its indices during AF. 
The commercially available devices to estimate CBP non-invasively, examine different 
aspect of ascending aortic response to ejected volume load to compute central blood 
pressure indices including central PP (CPP), CAIx75, and CAP.  The CPP is an indirect 
estimate of central pulsatile load and found to be an independent predictor of AF in 
middle aged participants (121). In elderly or advanced aortic stiffness, the CPP is of 
limited value because of the reduced  amplification of central systolic pressure wave (80). 
The CAP is calculated by the difference between the systolic summits as shown in Figure 
4.8.1. It represents systolic amplification induced by the reflective pressure wave that can 
be amplified in aortic stiffness. CAIx75 is calculated as a ratio between CAP and CPP 
(CPP/CAP x100) and adjusted for HR 75bpm. Both CAP and CAIx75 are indirect measures 
of aortic stiffness and are dependent on multiple variables including gender, height and 
baseline heart rate (179). In addition, CAP and CAIx comprise of high frequency signals 
that are not adequately characterised by GTF based devices (179). These CBP indices are 
not interchangeable due to the technical limitations posed by device software and 
characteristics of the population studied (136, 166, 167). For example, standardised CBP 





targets can be offered to the younger individuals with relatively increased aortic stiffness 
to prevent accelerated CV remodelling and AF.  
4.7  CONCLUSION  
As a modifiable factor, aortic stiffness evaluation is clinically important for detection of 
premature conduit vascular remodelling consequent to the increased central pulsatile 
load. Non-invasive CBP assessment devices require a standardised methodology that is 
relatively time efficient, operator independent and user friendly to improve incorporation 
into routine clinical use to detect accelerated central arterial stiffness that can lead to 
subsequent end organ injury including AF. Further work is needed to define the 
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GTF FF CSBP, CDBP, 
CPP, CAIx 
-6.4 (-13 to 1) 
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Physics Model FF CSBP, CDBP, 
CPP 
-4.9 (-11 to 1.6) 
 






























-3.6 (-9.6 to -2.4) 
CAIx= central augmentation index, CAP= central augmentation pressure, CDBP= central diastolic BP, CPP= 
central pulse pressure CSBP= central systolic BP, CPW= central pulse wave velocity, FF= fluid filled, GTF= 














CAVI= carotid-ankle vascular index, cf PWV= carotid-femoral pulse wave velocity, HR= hazard 
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Increased CV and ACM 




XCEL (133, 144, 









HR 1.28 (1.16 to 1.47) 
Compilor (20, 24, 
25) 
cf PWV Mechano-transducer ++ HR 1.24 (1.04 to 1.54) 
CAVI (225) cf PWV Sphygmomanometer +++ NA 
Arteriograph (51)  cf PWV Sphygmomanometer ++ NA 
 









HR 1.9 (0.9 to 3.8) 
Omron VP 1000 
(226) 
cf PWV Sphygmomanometer +++ HR 1.15 (0.98 to 1.3) 
Doppler 
Echocardiography 
















Impact of Atrial Fibrillation on Assessment of Central 
Blood Pressure and Aortic Stiffness Indices 
  
5.1  INTRODUCTION 
Due to its high prevalence, hypertension (HTN) confers the highest population 
attributable risk for atrial fibrillation (AF) development (15).  Several large epidemiological 
studies have also demonstrated both high-normal systolic blood pressure (<140 mmHg) 
and increasing pulse pressure, an indirect measure of aortic stiffness, to be independently 
associated with incident AF (10, 52, 118, 149). Further, both uncontrolled blood pressure 
and aortic stiffness have been shown to result in higher AF recurrences following catheter 
ablation (61, 227). Given the evidence of increased aortic stiffness even in subjects with 
high-normal systolic blood pressure, assessing aortic stiffness may be relevant towards 
comprehensive risk factor management in individuals with AF (34, 228). Despite been 
acknowledged as a precursor to HTN and an independent predictor of cardiovascular risk, 
aortic stiffness remains a largely unmet therapeutic target (229).  
Of the many non-invasive methods used to quantify aortic stiffness, carotid-femoral pulse 
wave velocity (cfPWV) is considered the current reference method due to its standardized 
technique, reproducibility and ease of measurement (229, 230). An expanding range of 
devices is now available for assessing central blood pressure (CBP) indices and aortic 





185). Therefore, the present study is designed to evaluate the validity and reliability of 
non-invasive estimation of CBP indices and cfPWV (SphygmoCor XCEL, AtCor Medical, 
Australia) during AF as compared to during sinus rhythm (SR) with reference to invasive 
measures.  
5.2  METHODS 
5.2.1 Study Population 
This study enrolled consecutive patients with symptomatic drug refractory paroxysmal or 
persistent AF referred for catheter ablation at our institution. Our inclusion criteria included AF 
patients with an age range of 20-80 years who were in SR and willing to provide informed consent 
for the study (Figure 5.8.1). Our exclusion criteria included patients with moderate to severe 
aortic root dilatation (>4.5cm) or moderate to severe aortic insufficiency, active malignancy, or 
recent (<4weeks) history of decompensated heart failure. The study protocol was prospectively 
registered (A prospective validation study to Investigate the role of Multi-modality central PULSE 
wave evaluation and its impact on Atrial Fibrillation outcome (IMPULSE AF) - Validation Study, 
ANZCTR, ACTRN12616001225404) with approval from the institutional ethics committee.  
5.2.2 Patient Preparation 
All patients provided informed consent and were studied in the fasting state under 
general anesthesia during their scheduled catheter ablation procedure prior to 
commencement of ablation protocol. All patients remained on uninterrupted oral 
anticoagulation while anti-arrhythmic drugs were ceased at least 5 days prior to the 
procedure. A transesophageal echocardiogram was undertaken to exclude left atrial 





first in SR and subsequently during AF that was induced by rapid atrial burst pacing from a 
decapolar catheter positioned in the coronary sinus. Hemodynamic and aortic stiffness 
measurements during AF were performed only after stabilization of the arrhythmia at 
least 10 minutes post-induction.  
5.2.3 Study Protocol 
5.2.3.1  Invasive Central Blood Pressure Measurements  
A 125 cm straight 4-Fr pigtail catheter with 4 side holes (SRD5287- Cordis, Miami, FL, USA) 
was placed in the aortic root through a 6F right radial arterial sheath (7cm Radiofocus, 
Terumo Medical, Tokyo, Japan). Invasive CBP was recorded by a fluid-filled manometer 
system (Sensis Vibe, Siemens Healthcare Germany). The transducer was zero calibrated at 
baseline and kept at the level of the mid-axillary line. The central pressure waveform was 
digitally recorded at 100Hz using the MacLab XT (GE Healthcare, Chicago, IL, USA) 
hemodynamic monitoring system. Central pressure indices were derived from averaging 
the pressure waveforms over 20 seconds. For each patient, an average of three central 
blood pressure readings were taken for comparison between invasive and non-invasive 
CBP indices. 
5.2.3.2 Non-Invasive Central Blood Pressure Estimations  
The SphygmoCor XCEL system was used to obtain non-invasive CBP estimates. It is an 
automated cuff based oscillometric device that acquires pressure waveform to assess 
brachial systolic and diastolic pressure. The central aortic pressure waveform is derived 
using proprietary transfer function, which is essentially a low-pass frequency filter applied 





assessment of CBP indices during SR (231, 232). The accuracy of automated oscillometric 
measures of blood pressure indices is known to be affected by the beat-to-beat variation 
during AF (233). To improve accuracy, we averaged three automated recordings to 
calculate CBP indices over 20 seconds each (234). Only the recordings fulfilling the 
waveform acquisition quality control criteria imposed by the device software were used.   
The acquired central pressure waveform was then used to quantify central systolic, 
diastolic, pulse and augmentation pressure. Central pulse pressure (CPP) was taken as the 
difference between central diastolic pressure and systolic peak. Central augmentation 
pressure (CAP) was derived by the difference between systolic peaks P1 and P2 of the 
central pressure waveform: P1 represents the ejected pressure wave, the amplitude of 
which is mainly determined by ventricular contraction and the PWV of the ascending 
aorta; P2 represents the reflected fraction of the ejected wave from peripheral segments 
of arterial tree. Central augmentation index was derived as a ratio between CAP and CPP 
that was automatically adjusted for heart rate (HR) of 75 beats per minutes (bpm) by the 
device software (Figure 5.8.2).  
5.2.3.3 Carotid-femoral Pulse Wave Velocity (cfPWV) Assessment  
The SphgmoCor XCEL estimates cfPWV by dividing the transit time expended by the 
ejected pressure wave to travel between carotid and femoral arteries over the surface 
distance between these two vascular points. The carotid and femoral pressure traces 
were averaged over 20 seconds to calculate the cfPWV in AF and during SR. These were 





example to illustrate CBP waveform and aortic PWV assessment is shown in Figures 
5.8.3A and 5.8.3B.  
5.2.4 Statistical Analysis 
Continuous variables were normally distributed and expressed as mean ± standard 
deviation. Pearson’s correlation analysis and Bland Altman plots were used to compare 
the non-invasive estimates to invasive CBP indices. Assumptions of a linear regression 
were found to be upheld, using scatter plots and histograms to assess normality of 
residuals and random scatter of variance (Figure 5.8.4). The mean values of CBP indices 
were compared by the linear mixed-effect model to estimate the interaction of AF and 
SR. Additionally, to evaluate the impact of heart rate on the comparisons, the mean heart 
rate was taken as an arbitrary threshold. The p-value of ≤0.05 was regarded as 
statistically significant. All statistical analysis was performed using SAS 9.4 (SAS Institute 
Inc., Cary, NC, USA). 
5.3  RESULTS  
Out of 58 individuals found suitable for the study, 33 were planned to have AF ablation 
and were approached to obtain informed consent. Two patients declined to participate in 
the study. The study cohort comprised of 31 patients with a mean age of 64±6 years (55% 
male) and mean CHA2DS2-VASc score of 1.9±0.7. Hypertension and dyslipidemia were 
highly prevalent amongst the study participants, who were overweight with preserved 
left ventricular systolic function and mild left atrial dilatation (Table 5.9.1). Angiotensin-
converting enzyme inhibitors or angiotensin II receptor blockers were used in 65% and 





5.3.1 Non-invasive versus invasive CBP Indices during SR and AF  
The estimated means of invasive and non-invasive CBP indices are listed in Table 5.9.2. 
The non-invasive appraisal of central systolic blood pressure (CSBP) was strongly 
correlated with the invasive measurements both in SR and during AF (Figure 5.8.5A: left 
and right panel respectively). Bland Altman analysis revealed that non-invasive method 
significantly overestimated CSBP by 3.2mmHg (Figure 5.8.5B: left panel) and 7.6mmHg 
(Figure 5.8.5B: right panel) during both SR and AF (mean heart rate 7119 and 8717 
bpm respectively). Notably, invasive measure of CSBP was found to be significantly lower 
during AF as compared to SR (mean -5.6 mmHg, 95% CI, -13.7 to 2.48, p=0.03). However, 
this was not seen with the non-invasive CSBP method (mean -1.25mmHg, 95% CI -8.6 to 
6.1, p=0.6). When analyzed according to low or high heart rate (taken as below or above 
the mean heart rate), there was no significant difference in CSBP estimates during SR. 
However over-estimation of CSBP was more noticeable during AF with higher ventricular 
rate (mean >87bpm) as shown in Figure 5.8.6B.  
Moderate but statistically significant correlations were seen between non-invasive and 
invasive measurements of central diastolic blood pressure (CDBP) during SR and AF (Table 
5.9.2).  Similarly, the non-invasive method over-estimated CDBP during both SR and AF 
(+10.4 mmHg, p<0.004 and +9.0 mmHg, p<0.001 respectively, Table 5.9.2). Interestingly, 
a stronger correlation was found between non-invasive and invasive central pulse 
pressure (CPP) during AF than SR (R2=0.70, p<0.001 vs. R2=0.45, p= 0.043 respectively). 
Bland-Altman analysis of non-invasive estimation of CPP showed statistically significant 
underestimation during SR (-7.0 mmHg, p=0.026) and non-significant difference during AF 





during SR and AF (21.24 vs 18.13 mmHg, p=0.44) and showed moderate correlation 
(R2=0.51, p<0.01). Central augmentation index (CAIx75) was also comparable during SR 
and AF (434 vs. 474 mmHg, p=0.05) with strong correlation (R2 = 0.76, p<0.01). A 
significant correlation between brachial and central BP was reported (Figure 5.8.7A and 
5.8.7B, left panels). However, as compare to invasive aortic assessment, significant 
amplification of pressure wave was recorded at brachial site.  (Figure 5.8.7A, right panel).  
5.3.2 cfPWV during SR and AF 
Our cohort has a normal cfPWV for their age with a mean value of 5.9  1.3 m/s and 6.5  
1.5 m/s during SR and AF respectively. A moderate but significant correlation was found 
between mean cfPWV during SR and AF (R2=0.55, p=0.001; Figure 8A: left panel). Overall 
cfPWV was significantly higher during AF as compared to during SR (+0.58m/s, 95% CI 0.1 
to 1.0 m/s, p=0.02; Figure 5.8.8A: right panel).  At heart rate above mean of 87bpm, 
cfPWV was significantly higher during AF vs. SR (+0.93 m/s, 95% CI 0.20 to 1.66, p=0.0016; 
Figure 5.8.8B: left panel). However, this was not seen at heart rate below mean of 87bpm 
(+0.27m/s, 95% CI -0.13 to 0.68, p= 0.17; Figure 8B – right panel).  
5.4  DISCUSSION 
To the best of our knowledge, this is the first study evaluating the validity of non-invasive 
assessment of CBP indices and cfPWV in AF. Our key findings using the SphygmoCor XCEL 
are as follows: First, non-invasive CSBP & CDBP indices demonstrate moderate to strong 
correlation with invasive measures (R2 0.48 to 0.93) and < 15% over-estimation during SR 
and AF. Second, non-invasive central aortic stiffness estimation of CPP demonstrates 





estimation during SR and AF. Third, non-invasive aortic stiffness indices of CAP, CAIx75 & 
cfPWV when measured during AF and SR demonstrate moderately strong correlation (R2 
0.51 to 0.76). Last, CBP and aortic stiffness can be reliably assessed non-invasively during 
AF especially when ventricular rate is well-controlled. 
5.4.1 Effects of AF on CBP indices  
The evaluation of BP during AF is challenging due to beat-to-beat variation of stroke 
volume and rapid change in diastolic ventricle filling, resulting in increased BP variability. 
The SphygmoCorXCEL is an automated oscillometry based BP device whereby abrupt 
changes in the pressure wave amplitude during AF can affect reading accuracy although it 
is well known that oscillometric estimation of systolic BP is reasonably accurate during AF 
as opposed to diastolic BP (233). To improve accuracy of measurements, we took a mean 
of three consecutively assessed CBP indices recorded over 20 seconds during AF with the 
SphygmoCorXCEL device. Reassuringly, we found moderate to strong correlations 
between non-invasive estimation of CSBP and CDBP with direct invasive measurements.  
5.4.2 Effects of AF on Aortic Stiffness Assessment   
Aortic stiffness was assessed by cfPWV evaluation with SphymoCor XCEL for our cohort. 
The baseline increase in HR and beat-to beat variability during cfPWV assessment can 
reduce the overall accuracy of central pulse wave velocity evaluation. To reduce the 
impact of HR variability during AF we recorded pressure waveforms for an average of 
20seconds during cfPWV evaluation and took a mean of three consecutive assessments. 
Our cohort has normal cfPWV with a mean of 5.9  1.3 m/s and 6.5  1.5 m/s during SR 





which is within acceptable variance range for the mean age of our cohort and clinically 
non-significant.(235) Moreover, the mean difference in cfPWV estimation was even 
smaller at 0.2m/s, (95% CI -0.46 to 0.86, p=0.527) during controlled AF (HR of <87bpm).  
5.4.3 Technical Considerations 
None of the currently available devices used to estimate CBP indices and aortic stiffness 
have been validated against invasive ascending aortic pressure during AF. Majority of the 
devices including SphygmoCor XCEL acquire the peripheral pressure waveform and 
calibrate it to peripheral systolic and diastolic BP. A mean error of more than 10mmHg 
was reported during calibration of peripheral pressure waveform in irregular rhythm 
(203) resulting in over or under-estimation of non-invasive CBP indices (236, 237). The 
SphygmoCor XCEL uses brachial arterial oscillometry to record peripheral pressure 
waveform that is then adjusted to systolic and diastolic brachial BP. The calibrated 
brachial pressure wave is then subjected to Generalized Transfer Function to derive the 
central pressure wave form (231), (236).  Hence, the error inducted during calibration of 
peripheral pressure wave can affect CBP estimates to an acceptable range of 5 ± 8mmHg 
during SR (186, 190, 191, 236). This observation is further supported by the strong 
association noted by the current study between non-invasive central and brachial blood 
pressure, suggesting that the accuracy of CBP is affected by the calibration error 
instituted during brachial artery oscillometry to determine systolic and diastolic BP (191). 
Previous validation studies reported under-estimation of CSBP and over-estimation of 
central diastolic BP by SphygmoCor XCEL (238). We recorded a non-significant over-





previous reports (190, 239). However, further analysis of previously published validation 
studies revealed over-estimation of CSBP by non-invasive devices when systolic BP ranged 
between 110-120 mmHg, which is similar to the mean CSBP of our cohort during AF and 
SR (238, 240). Additionally, the trend of over-estimation was consistent irrespective of 
underlying rhythm and the reported mean bias of the non-invasive CBP indices by the 
current study is within acceptable limits of <5mmHg (184, 232, 237).  
5.5  STUDY LIMITATIONS 
The size of our cohort was relatively small. However, our validation study has a normal 
distribution of variants with adequate statistical power to determine the impact of AF on 
CBP indices assessment (Figure 5.8.4). Most of our subjects (70%) were hypertensive and 
on blood pressure lowering medications that can affect CBP indices. Additionally, the CBP 
and aortic stiffness assessment was performed under general anesthetic in a cohort with 
a relatively lower burden of coronary artery disease as compared to previous validation 
studies, which were performed under light sedation in participants enlisted for coronary 
angiography with a relatively increased use of vasoactive drugs (185, 190). Nevertheless, 
comparisons of non-invasive to invasive measures were performed within the same 
patient and the effects of vasoactive and anti-hypertensive treatment are therefore 
minimized. Our cohort consisted of middle-aged Caucasians and it remains unclear 
whether the results can be generalized for non-Caucasian individuals in other age 





5.6  CLINICAL IMPLICATIONS  
Our key finding regarding the validity of non-invasive assessment of aortic stiffness during 
AF has important clinical implications. It has potential to extend the clinical applicability 
of aortic stiffness assessment in the AF population irrespective of the prevailing heart 
rhythm. Indeed, further studies are needed to delineate the association between aortic 
stiffness and AF outcomes in relation to targeting aortic stiffness as a modifiable risk 
factor. It is plausible that patients with sub-clinical central aortic stiffness carry 
heightened risk for progressive atrial remodeling despite ‘normal’ peripheral BP readings.  
5.7  CONCLUSION 
Central blood pressure and aortic stiffness indices can be reliably estimated non-





















































CAIx75= Central Augmentation Index corrected for heart rate 75bpm, CAP= central augmentation 













Figure 5.8.3A: Case Example Illustrating CBP Waveform Assessment  
 
(Aix75= augmentation index, AP= augmentation pressure, DP= diastolic pressure, HR= heart rate, , 























Figure 5.8.4: Scatter Plots and Histograms to Illustrate Normal Distribution 















Figure 5.8.6: Bland- Altman Plots Illustrating the Agreement between 
Invasive and Non-Invasive CSBP during Sinus Rhythm and Atrial Fibrillation 







Figure 5.8.7A: Systolic Brachial and Invasive CSBP during Sinus Rhythm- 





Figure 5.8.7B: Systolic Brachial and Non-Invasive CSBP during Sinus 















































(ACE-I= Angiotensin-converting enzyme inhibitor, ARB= Angiotensin II receptor blocker, * 
= All persistent AF patients were cardioverted at least a few weeks pre ablation and were 
in sinus rhythm at the time of CBP assessment) 
 
 
Characteristics Total (n=31) 
Age (years) 64 ± 6 
Male, n (%) 17 (55) 
Body mass index (kg/m2) 28 ± 5 
Hypertension, n (%) 21 (68%) 
Diabetes mellitus, n (%) 6 (19%) 
Dyslipidemia, n (%) 24 (77%) 
Coronary artery disease, n (%) 3 (9%) 
Left ventricular ejection fraction (%) 62 ± 8 
Left atrial volume indexed to BSA (ml/m2) 30.5 ± 7.4 
Diastolic function e/e’ (septal)  10.5 ± 3.5 
Ascending aortic diameter, anteroposterior (cm) 3.3 ± 0.4 
*Persistent AF, n (%) 11 (35%) 
CHA2DS2-VASc score 1.9 ± 0.7 
HAS-BLED score  1.2 ± 0.6 
Medications  
ACE-I/ARB, n (%) 20 (65%) 
Beta-blockers, n (%) 15 (48%) 
Calcium channel blockers, n (%) 6 (19%) 
HMG-CoA reductase inhibitors, n (%) 24 (77%) 





















Correlation Analysis Bland-Altman Analysis 
R2 P-value 
Mean Difference 




122  22 118  22 0.93 <0.001 +3.2 (0.1 – 6.3) 0.04 
Central SBP 
during AF 
121  24 113  25 0.86 <0.001 +7.6 (5.1 – 10.1) < 0.001 
Central DBP 
during SR 
81  15 71  12 0.48 <0.01 +10.4 (5.1 – 15.8) < 0.004 
Central DBP 
during AF 
80  13 71  13 0.50 <0.01 +9.0 (5.4 – 12.5) < 0.001 
Central PP 
during SR 
41  15 48  16 0.45 <0.04 -7.0 (-12.9 – -0.9) 0.026 
Central PP 
during AF 
41  16 42  15 0.70 <0.001 -1.3 (-5.0 – 1.9) 0.40 
Mean heart rate during atrial fibrillation (AF) and sinus rhythm (SR) was 8718 and 7119 bpm respectively. 












Assessment of Residual Aortic Stiffness in AF: Exploring 
Central Haemodynamics Response to Exercise 
 
 
6.1  INTRODUCTION 
Exercise represents a physiological stress that can help expose sub-clinical cardiovascular 
(CV) remodelling to help predict increase risk of adverse events (241, 242).  
A hypertensive response to exercise defined as brachial systolic BP of > 210mmHg in 
males and >190mmHg in females, is linked to future risk of hypertension and its related 
end organ injury including left ventricle hypertrophy (242).  The precise mechanism of 
hypertensive response to exercise (HRE) is yet to be elucidated. However, endothelial 
dysfunction, conduit arterial stiffness, exaggerated sympathetic response and augmented 
neurohormonal response including angiotensin II are recognised as important 
contributors (243).  Considering the significant difference in pulsatile load between 
central and brachial arterial tree (132), central haemodynamic assessment during exercise 
may better predict the  CV outcomes. Further, aortic stiffness as a modifiable factor and 
marker of persistent high central blood pressure is acknowledged as a novel risk in atrial 
fibrillation (AF) (49, 61, 121, 244). Estimation of central blood pressure and its indices 
response to exercise can potentially unmask sub-clinical vascular remodelling in AF. This 
may improve AF management further by targeting the modifiable factors associating the 
arrhythmia with central arterial stiffness (121). Therefore, the aim of the current study 
was to characterise the central and peripheral blood pressure indices at rest and their 





6.2  METHODS 
6.2.1 Participants 
The study enrolled 46 consecutive patients with history of paroxysmal and persistent AF 
being considered for ablation at Centre for Heart Rhythm Disorders, University of 
Adelaide, Adelaide, Australia. The Heart Rhythm Society Consensus definitions were used 
to define paroxysmal and persistent AF (245) . The study included patients with an age 
range of 20-80 years and willing to provide informed consent. All patients were found to 
be in sinus rhythm. Exclusion criteria were: moderate to severe aortic root dilatation 
(>4.5cm); moderate to severe aortic insufficiency; recent cardiac surgery; active 
malignancy; recent (<4weeks) history of decompensated heart failure; uncontrolled 
severe hypertension (resting BP > 180/120)(246); permanent AF; or inability to perform 
exercise stress test.  
In addition, 31 consecutive patients with no documented history of AF, who were 
undergoing exercise stress test (EST) to exclude exertional angina or arrhythmia were 
recruited as controls.  
All participants provided written informed consent to the study protocol that was 
reviewed and approved by the Clinical Research Ethics Committees of the Royal Adelaide 
Hospital, University of Adelaide. The study protocol was prospectively registered 
(ACTRN12618000074291).  
6.2.2 Definitions 
The following definitions were used to characterise the patient for the study: 
• Hypertension was considered to be present if they were actively treated for the 





patients with average systolic brachial BP of 127 ± 7 mmHg at rest. The rest of the 
45% (25/56) patients had grade I-II HTN with a mean BP of 153 ± 10 mmHg despite 
ongoing anti-hypertensive treatment.  
• Diabetes mellitus was classified as defined by the European guidelines (247) or if 
they were actively treated for the condition; 
• Dyslipidemic as defined by the European guidelines (247); 
• Coronary artery disease (CAD) if they had known stenosis of >50% of a major 
coronary artery or had undergone coronary revascularization. 
6.2.3 Patient Preparation 
All participants were advised to avoid heavy meal and refrain from coffee and smoking 
before evaluation of central blood pressure (CBP) indices at rest and early recovery 
(within 60 seconds post exercise).  
6.2.4 Study Protocol 
The SphygmoCor XCEL (AtCor Medical, Australia) system was used to record non-invasive 
CBP estimates. The SphygmoCor XCEL was chosen amongst the available devices as it is 
extensively validated and widely used in epidemiological as well as clinical settings to 
record CBP indices (132, 186). It is an automated oscillometric device that acquires 
pressure waveform by applying pressure cuff over the brachial artery approximately 
midway between the shoulder and elbow. This pressure waveform is further calibrated to 
brachial pressure indices and subjected to a proprietary generalized transfer function, 






6.2.5 Data Collection 
The baseline brachial and CBP was recorded following 10mins of rest during sitting. The 
participants then completed an exercise workload as per Bruce Protocol by using a 
treadmill during which 85% age predicted heart rate was targeted. The BP response to 
exercise was estimated within 60 seconds post exercise to ensure quality control of the 
recordings by avoiding motion artefacts.  
6.2.6 Central Pulse Wave Analysis 
We recorded oscillometric central pressure waveforms by applying pressure cuff from 
SphygmoCor XCEL device (AtCor Medical, Australia) over the right arm. Each 
measurement cycle consisted of a brachial blood pressure calculation followed by a sub-
systolic pressure recording to generate a corresponding aortic waveform by using a 
validated transfer function (188, 191). We averaged two recordings to calculate CBP 
indices over 20 seconds. Only the recordings fulfilling the quality control criteria imposed 
by the device software were used to perform the analysis. The acquired aortic pressure 
waveforms were used to quantify central systolic, diastolic, pulse and augmentation 
pressure at rest and post exercise. Central pulse pressure (CPP) was derived by deducting 
diastolic pressure from systolic peak, Figure 6.9.1. Central augmentation pressure (CAP) is 
recorded by estimating the difference between systolic peaks (P2-P1). Here, P1 is the 
ejected pressure wave, the amplitude of which is mainly determined by ventricular 
contraction and the pulse wave velocity (PWV) of the ascending aorta. In contrast, P2 is 
the reflected fraction of the ejected wave from peripheral segments of arterial tree. 
Reflection index (RI) was derived by SphygmoCor XCEL software by dividing peak 





addition, augmentation index (AIx) was also calculated by the formula AP / PP x 100.  The 
device software further corrected AIx for a heart rate at 75 beats per minute (AIx75) to 
avoid influence of fluctuating heart rate on AIx recordings (248). The comparison of the 
corresponding CBP indices at rest and post-exercise was performed and further adjusted 
to the co-variates to determine the change with exercise.  
6.3 STATISTICAL ANALYSIS 
The statistical software used was SAS 9.4 (SAS Institute Inc., Cary, NC, USA). The 
continuous values for a range of brachial and CBP outcomes at rest and post exercise 
were expressed as mean ± SD for patient groups defined by history of AF.  A mean change 
between resting and exercise index is calculated as change= (exercise value) – (resting 
value). The continuous variables were initially compared by using Student’s t-test 
between AF and non-AF groups. The frequency distributions of the categorical variables 
amongst the two groups were compared by the Chi Square test. The difference in 
“change” in BP indices with exercise between the groups (AF vs non-AF) was analysed by 
using linear regression models. Robust standard errors were specified to account for the 
unequal variance in outcomes observed between the two groups. The mean estimates of 
differences were further adjusted for age, gender, resting heart rate (HR) and anti-
hypertensives. The corresponding 95% confidence intervals were reported and p-values 
of <0.05 were considered as significant. The study had 80% power to detect a change 





6.4  RESULTS 
6.4.1 Characteristics of the Study Cohort 
Figure 6.9.2 presents a CONSORT diagram of study recruitment, with none of patients 
declining to consent. The study cohort comprised of 77 patients with a mean age of 62 ± 
14 years (69% male) and average CHA2DS2VASc score of 1.67 ± 0.4. The demographic 
details of the participants are listed in Table 6.10.1. The participants had a mean body 
mass index (BMI) of 27 ± 4kg/m2 and a high prevalence of hypertension (72%). In terms 
of anti-HTN regime, majority of our participants (80%) were taking Angiotensin-
converting enzyme inhibitors/Angiotensin receptor II blockers (ACE-I/ARB). Overall, the 
incidence of diabetes was 17%. Majority (95%) of the participants had normal LV systolic 
function with mean ejection fraction (EF) of 61 ± 7.3 % on echocardiography. Only 5% of 
the cohort had impaired LV systolic function with reported mean EF of 42 ± 11 %. 
Likewise, 83% of the patients had normal left atrial (LA) volume (<36mls/m2) with an 
average LA size of 29 ± 4 mls/m2. Only 17% of the participants had dilated LA with a mean 
of 42 ± 3.9 mls/m2 on echocardiography. 
6.4.1.1 Participants with History of AF   
The mean age of the participants with history of AF was 67 ± 8 years and 69% were male. 
The average resting brachial and central BP was 136 ± 16 and 123 ± 13 mmHg 
respectively. Majority (80%) of patients with history of HTN and AF were on ACE-I/ARB 
based therapy.  However, 52% of the AF cohort were taking regular beta-blockers with an 
average resting heart rate (HR) of 67 ± 12 bpm. The mean CHA2 DS2VASC score for the AF 





6.4.1.2 The Controls 
The mean age of the controls was 54.4 ± 11 years, 69% were males, as listed in 
Table6.10.1. The average resting brachial and central BP was 142 ± 15 and 128 ± 13 
mmHg respectively. In controls, hypertension was found to be the most common 
cardiovascular risk and 80% of hypertensive patients were on ACE-I/ARB based therapy. 
Only 19% of the controls were on regular beta-blockers with a mean HR of 71.5 ± 12 bpm. 
The mean CHA2 DS2VASC score for the control group was 1.5 ± 0.5. 
Compared to controls, the participants with history of AF were older (mean age 67 ± 8 
years vs 54.4 ± 11 years, p<0.001) and recorded to have lower resting brachial (136± 16 
mmHg vs 142 ± 15 mmHg, p= 0.015) and central systolic blood pressure (123 ± 13 vs 128 ± 
13 mmHg, p=0.006). However, as compare to controls, increased resting Aix75 
(Aix75 >30) was more prevalent in AF group (41 vs 25%, p<0.001, Table 6.10.2). In terms 
of anti-HTN regime, 80% of total cohort was on ACE-I/ARB. However, beta-blockers were 
more frequently used in AF patients (AF 52% vs controls 19%, p=0.001) as listed in Table 
6.10.2. 
6.4.2 Exercise Stress Test  
Participants were subjected to exercise on treadmill as per Bruce protocol to achieve 85% 
of age predicted target heart rate (220-Age). Their brachial and CBP indices response to 
exercise was characterised at rest and during early recovery. The participants with AF had 
reduced effort tolerance as compared to controls and managed to exercise for an average 
7.4 ± 2.5 vs 9.5 ± 1.76 mins, p<0.001. The incidence of exercise induced HTN (peak 
brachial BP of >210mmHg) was comparable between the two groups (10% vs 7%, p=0.4). 





Compared to patients with documented AF, the incidence of positive exercise stress test 
concerning ischemia was more commonly reported in the controls (19 vs 6%, p <0.001).  
6.4.3 Brachial BP Indices at Rest  
In patients with history of AF, the brachial BP was better controlled at rest (AF 136± 16 
mmHg vs Control 142 ± 15 mmHg, p= 0.015). After adjusting for age, gender, resting HR 
and anti-hypertensives the resting brachial blood pressure remained significantly low in 
patients with history of AF than controls (difference 9.0mmHg, 95% CI -2.8 to 16, 
p=0.015) as shown in Table 6.10.3. However, no significant difference was recorded for 
adjusted resting brachial diastolic (4.7 mmHg, 95% CI 0 to 9.5, p=0.052) and pulse 
pressure (4.6 95% CI -1.9 to 11.1, p= 0.17) between the two groups.   
6.4.4 Exercise Response of Brachial BP Indices  
In response to moderate exercise, a comparable amplification in brachial systolic blood 
pressure was recorded between participants with history of AF and controls (166 ± 20 vs 
174 ± 19 mmHg, 8.4mmHg, 95% CI -1.7 to 18.4, p= 0.09), Table 6.10.4. Furthermore, no 
significant difference was noted concerning exercise response to adjusted brachial 
diastolic ( 91 ± 15 vs 96 ± 12mmHg, 5 mmHg, 95% CI -1.7 to 11, p= 0.15) and PP (75 ± 17 
vs 78 ± 15mmHg , 3mmHg , 95% CI -5.1 to 12, p=0.43) between the two groups, Table 
6.10.4.  
Additionally, we analysed the mean change in central and brachial BP indices in response 
to exercise between AF and controls. We found no difference in adjusted means between 
the two groups except a significant amplification in CAP in response to exercise in 





6.4.5 Resting Central BP Indices  
The resting central systolic blood pressure was better controlled in patients with history of 
AF (mean CBP with AF 123 ± 13mmHg vs mean CBP in controls 128 ± 13mmHg, p=0.006). 
After adjusting for co-variates including age, gender, anti-hypertensives and resting heart 
rate the difference in resting central systolic blood pressure between patients with history 
of AF and controls remained significant (9.0mmHg, 95% CI 2.6 to 15.3, p=0.006) as shown 
in Table 6.10.3. There was no difference noted in adjusted CPP (4.4mmHg, 95% CI -1.1 to 
10, p=0.12), CAP (1.8mmHg, 95% CI -2.4 to 6.1, p=0.40), RI (5.8, 95% CI -2.3 to 13.9, p= 0.16) 
and AIx75 (-2.0, 95% CI -9.8 to 5.9, p=0.62) at rest.  
A significant amplification of systolic pressure wave was recorded at brachial arterial site  
for patients  with history of AF (mean brachial BP 136 ± 16 mmHg vs mean CBP 123 ± 
13mmHg, p<0.001) and controls (mean brachial BP 142 ± 15 vs mean CBP 128 ± 13 mmHg, 
p<0.001).   
6.4.6 Exercise Response of CBP Indices 
In addition to central systolic and diastolic pressure, CBP indices were recorded non-
invasively to report central arterial response to exercise. A comparative analysis by using 
regression model was used to delineate variance in brachial and CBP indices between AF 
and non-AF groups.  The recorded mean differences were further adjusted for age, 
gender, heart rate and anti-hypertensives. Overall, no significant difference was recorded 
in CBP response to exercise between participants with history of AF and controls (147 ± 
16mmHg vs 150 ± 15mmHg, (difference 2mmHg 95% CI -3.7 to 12, p=0.29) as listed in 
Table 6. However, a significant increase in adjusted exercise CAP was noted for patients 
with history of AF (5.7mmHg, 95% CI 0.4 to 11.7, p=0.04) indicating impaired vascular 





recorded for CPP (0.8 mmHg, 95% CI -6.3 to 8.0, p=0.82), central Aix75 (-2.1, 95% CI -13.7 
to 9.4, p= 0.72) and RI (0.8, 95% CI -8.5 to 9.9, p= 0.87) response to exercise between the 
two groups as shown in Table 6.10.6.  
Additionally, we compared the mean change in the central and brachial BP indices of 
hypertensive and normotensive patients irrespective of AF history. No statistically 
significant difference was found between normotensive and hypertensive patients 
concerning CBP estimates at rest (123 ± 13 mmHg vs 121 ± 14mmHg, p= 0.54) or post 
exercise (146 ± 16mmHg vs 147 ± 16 mmHg, p=0.44).  
6.5  DISCUSSION 
6.5.1 Major Findings 
Hypertension remains a dominant attributable risk for the development and progression 
of AF. Appropriate therapy to control BP is essential to improve AF outcomes. Here we 
evaluate the role of central blood pressure measurements. The current study illustrated 
an important finding of residual yet sub-clinical central arterial stiffness in patients with 
AF, suggested by increased prevalence of central AIx75 at rest and significantly amplified 
response of CAP to moderate exercise. The current study also highlighted the potential 
role of exercise stress testing to unmask residual aortic stiffness despite normal resting BP 
indices in AF. As a modifiable factor aortic stiffness is of independent value to predict AF 
outcomes (61, 119-121, 173).   
6.5.2 Increased Incidence of Resting Central AIx75 in AF 
Despite a relatively better controlled central systolic BP, we found increased incidence of 
resting central Aix75 in our AF group after adjusting for ageing. The central Aix75 is a ratio 





is derived by the formula Central AIx75= CAP/CPP x 100 (249). The distribution of central 
Aix75 can be variable due to age related central arterial stiffness and central Aix75 >30 is 
considered high for the age group of our cohort (249). However, no significant statistical 
difference was recorded in central AIx75 post exercise between the AF and control 
groups. Increased central Aix75 and CPP are the recognised but indirect CBP indices 
reflective of aortic stiffness (163, 250). Hence, the independent value of these indices to 
predict cardiovascular and AF outcomes is yet to be confirmed (61, 250). The CPP is 
derived by subtracting central diastolic from central systolic BP (Figure 6.9.1). We 
reported no change in CPP with exercise in our cohort. One of the possible explanation is 
that SphygmoCor XCEL under-estimates central systolic and over-estimates central 
diastolic pressure (80, 166). This leads to significant under-estimation of CPP. Likewise, 
central Aix75 is a ratio and dependent on multiple variables. Conceivably, an error 
introduced during estimation of CPP can impact on the reported central Aix 75 value and 
its overall difference between the two groups (248, 251).  
6.5.3 The Potential Role of Characterising Exercise Response of CAP in AF Patients 
In our study we reported increase CAP response to exercise in AF participants. The CAP is 
derived from aortic pressure waveform as the difference between the early and late 
systolic summits. The early systolic wave is predominantly formed by forward pressure 
wave generated by left ventricle ejection. On the other hand, the late systolic peak is 
influenced by the vascular compliance of the subject- a stiffer arterial tree leads to 
amplification of propagating wave at the infliction point ensuing increased CAP (252). A 
physiological increase in heart rate during exercise can unmask sub-clinical aortic stiffness 





a relatively stiffer vasculature results in amplification of late systolic peak recorded as 
exaggerated CAP during exercise in our AF cohort.   
6.5.4 Role of Exercise Stress Test in Characterising Residual Aortic Stiffness in AF 
We estimated BP response to exercise as this “physiological stress” has mechanistic 
relevance correlating HTN with AF. An exaggerated response of BP to moderate exercise 
reflects an overactive sympathetic response and/or endothelial dysfunction with vascular 
remodelling that prevent appropriate physiological vasodilation in response to exercise 
(242, 243).  The above factors are associated with aortic stiffens and may explain its 
correlation with HTN and increased AF risk. However, studies reported conflicting data 
associating hypertensive response to exercise with ventricular and conduit arterial 
remodelling (243, 254). The difference in baseline characteristics of participants with 
variable intensities and modalities of exercise may help explain the inconsistencies in the 
reported data. In general, hypertensive response to exercise is observed in aortic stiffness 
(76). This may highlight the underlying mechanism associating exercise induced 
hypertension with aortic stiffness and CV remodelling including increased risk of AF.  
Nonetheless, a practical question is how to diagnose and manage a sub-clinical residual 
vascular remodelling to improve risk factor modification and CV outcomes. The revised 
HTN guidelines has reduced the thresholds to instigate pharmacotherapy and advocated 
aggressive risk factor management to achieve BP treatment targets (27). However, the 
role of exercise induced HTN and aortic stiffness as a surrogate for persistently high CBP 
in sub-clinical HTN was not explored. Even AF was not recognised as an index of target 
organ injury in HTN.  The CBP indices response to exercise may help improve risk factors 





6.6  CLINICAL IMPLICATIONS 
Central arterial stiffness is an independent driver of AF. The body of literature defining BP 
targets to improve AF outcomes is evolving. Additionally, patients presenting with PAF 
and no identifiable conventional risk may benefit from assessment of sub-clinical aortic 
stiffness. Aortic stiffness can be estimated by a bedside recording of pulse pressure. 
Further, assessment of central hemodynamic response to exercise is clinically applicable 
and can help expose residual aortic stiffness as one of the possible mechanisms 
associating HTN with AF. The current study is very relevant in this regard. We explored 
the potential role of central hemodynamic response to exercise to further advance clinical 
application of risk factors modification in AF and to improve arrhythmia outcomes.  
6.7 LIMITATIONS 
Our study has the following limitations. First, it was an observational single centre study 
exploring the role of exercise stress testing to unmask central arterial remodelling in 
patients with AF. Second, majority of our subjects (80%) were hypertensive and taking 
active treatment that can potentially lower peripheral and CBP indices. In addition, the 
cohort selected for analysis was predominantly consisted of middle-aged Caucasians. It 
remains unclear whether the study results can be generalized for younger or older or 
non-Caucasian individuals. Finally, due to the existence of different exercise testing 
protocols, the results of our study pertain to the use of treadmill exercise according to the 
standardised Bruce protocol to achieve age predicted target HR of 85%. Despite the 
inherent limitations of an observational study our work has highlighted the association of 





6.8  CONCLUSION  
As a modifiable factor, aortic stiffness associating HTN with AF, still represents an unmet 
clinical need. Central haemodynamics response to moderate exercise can potentially 
unmask residual aortic stiffness in patients with AF. Further confirmation of our findings 
in a large prospective multi-centre setting will help address the gap in evidence to 

































Figure 6.9.1: Central Aortic Pressure Waveform, Illustrating 











(CAIx75= Central Augmentation Index corrected for heart rate 75bpm, CAP= central augmentation pressure, 
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Table 6.10.1: Characteristics of the Study Cohort 
 
 
(ACE-I/ARB= Angiotensin-converting enzyme inhibitors/Angiotensin receptor II blockers, BMI=Basal 






















Age (years) 61.8 ± 13.7 66.8 ± 8.2 54.4 ± 16.7 <0.001* 
Male (n, %) 53 (68.8) 32 (69.6) 21 (67.7) NS 
BMI (kg/m2) 27.5 ± 4.1 27.3 ± 3.8 27.7 ± 4.5 NS 
Hypertension (n, %) 56 (72.7) 37 (80) 24 (80) 0.21 
Diabetes Mellitus (n, %) 13 (16.9) 6 (13.0) 7 (22.6) 0.13 
Central Systolic BP (mmHg) 125 ± 13 123 ± 13 128 ± 13  0.006* 
Brachial Systolic BP (mmHg) 124 ± 14 136 ± 16 142 ± 15 0.015* 
Left Ventricle Ejection  
Fraction (EF%) 
61.3 ± 7 61±7 61 ± 7.3 NS 
Left Atrial Volume (mL/m2) 31.1 ± 6.6 31.5 ± 6.9 30.5 ± 6.3 NS 
CHA2S2VASC score 1.67 ± 0.4 1.9 ± 0.6 1.5 ± 0.5 NS 
Resting Heart Rate (bpm) 69.0 ± 12.6 67.3 ± 12.5 71.5 ± 12.5 NS 
Medications  
   
ACE-I/ARB (n, %) 61 (80.3) 37 (80.4) 24 (80.0) NS 
Beta-Blockers (n, %) 30 (39.0) 24 (52.2) 6 (19.4) 0.001* 







Table 6.10.2: Prevalence of High BP Indices in our Cohort 
 











Blood Pressure Index 
 
All patients (N=77) 
 
History of AF 
(n=46) 
  
No history of AF   
(n=31) 
 















High Resting CPP  
















High Resting Central  
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High Resting Central  
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Pulse Pressure 






























History of AF 
(n=46) 
No history 











125±13 123±13 128±13 9 
(2.6 to 15.3) 
0.12 0.006* 
Central DBP  
(mmHg) 
83±9 81±8 86±10 4.5 
(0.5 to 8.6) 
0.023* 0.03* 
CPP (mmHg) 41±12 41±13 41±11 4.4 
(-1.1 to 10) 
0.9 0.12 
CAP(mmHg) 12±9 12±8 11±11 1.8  
(-2.4 to 6) 
0.5 0.40 
Aix75 23.6±16 43±25 31±21 -2  
(-9.8 to 5.9) 
0.25 0.62 
RI  63±17 64±17 60±18 5.8  




138±16 136±16 141±15 9.3  




83±10 81±8 86±12 4.7  




55±14 54±14 55±12 4.6  
(-1.9 to 11) 
0.79 0.17 
*= statistically significant p-value, AF= Atrial fibrillation, Aix75= Adjusted augmentation index at heart rate 
of 75bpm, BP= Blood pressure, CAP= Central augmentation pressure, CPP= central pulse pressure, DBP= 













Table 6.10.4: Estimated Means for BP Indices Post Exercise 
 
*= statistically significant p-value, AF= Atrial fibrillation, Aix75= Adjusted augmentation index at heart rate 
of 75bpm, BP= Blood pressure, CAP= Central augmentation pressure, CPP= central pulse pressure, DBP= 
























148±15 147±16 150±15 4.2 
(-3.7 to 12) 
0.44 0.30 
Central DBP  
(mmHg) 
92±12 89±11 97±13 5.0 
(0.6 to 10.5) 
0.004* 0.08 
CPP (mmHg) 55±15 58±14 52±15 -0.8 
(-8.0 to 6.3) 
0.9 0.12 
CAP(mmHg) 14±13 18±12 9±12 5.7 
(1 to 11.7) 
0.06 0.04* 
Central Aix75 30±21 30±16 31±28 2.1  
(-9.4 to 13.7) 
0.25 0.7 
RI  67±17 64±17 60±18 5.8  




169±20 165±20 174±19 8.4  




93±14 90±14 97±12 5.0  




76±16 77±15 75±17 3.4 







Table 6.10.5: Adjusted Mean Change in Brachial BP Indices in Response to 
Exercise 
 































       
   AF history 136 ± 16 165 ± 20 30± 17  
-2.8 





(-5.24 to 13.07) 
 
0.394 
   No AF history 141± 15 174± 19 33 ± 16 
Brachial Diastolic 
Pressure (mmHg) 
       
   AF history 81± 8  86± 12 6±12  
-0.8 





(-6.15 to 7.37) 
 
0.856 
   No AF history 90± 14 97± 12 7±10 
Brachial Pulse 
Pressure (mmHg) 
       
   AF history 54±14 77± 15 23 ±  17 2.9 


























































































AF history 81± 8 89±10 7±9  
-3.13 
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(AF=atrial fibrillation, AP= augmentation pressure, BP= blood pressure, DP= diastolic pressure, P= p-value, 





























AF is the most common sustained arrhythmia and emerging data has elucidated the 
strong correlation of the arrhythmia with uncontrolled CV risks. Amongst these 
modifiable risks, HTN is the most common population attributable factor associated with 
AF. However, treatment goals for blood pressure in AF is still indistinct. This thesis 
evaluates the role of CBP indices and aortic stiffness to better characterise HTN in atrial 
fibrillation. Additionally, it describes the association of CBP and aortic stiffness with AF to 
improve ongoing risk factor management and to help device better preventative 
strategies in AF.  
Chapter-1 provides a comprehensive review of the literature linking HTN and AF. HTN is 
the most common risk associated with AF and better definitions of treatment targets are 
required for escalating global burden of the disease to prevent AF. Further, the burden of 
HTN and the impact of revised AHA guidelines for diagnosis, classification and 
management of HTN was discussed. Additionally, the complex patho-physiological nexus 
relating AF with HTN was re-visited and an assessment tool is proposed to better 
characterise atrial remodelling and end organ injury due to HTN.  Chapter-2 summarises 
the association of pre- HTN and new-onset AF by presenting the systematic review and 
meta-analysis of current published literature. Pre-HTN was defined as a BP range of 120-
139/80-89mmHg by the selected studies. It was found to be independently associated 
with new-onset AF and increases the absolute risk of arrhythmia by 27%. Moreover, as 





was reported in pre-HTN resulting in escalated risk of HTN induced end organ injury and 
CV events.   
As compared to brachial BP indices, central haemodynamic assessment was reported to 
be more relevant in predicting HTN induced end organ injury and AF outcomes.  
Population studies revealed that up to one fifth of the participants characterised as 
“normotensives” based on their brachial blood pressure had aortic stiffness due to 
persistently high central blood pressure. Chapter 3 presents the systematic review and 
meta-analysis of all the published prospective trials associating increased aortic stiffness 
independently to AF, cardiovascular and all-cause mortality. Increased aortic stiffness, as 
a surrogate marker for persistently high central blood pressure was independently 
associated with a 33% augmented risk of new-onset AF. The increased cardiovascular and 
mortality risk inflicted by raised aortic stiffness was also confirmed. Chapter 4 evaluates 
the non-invasive assessment of CBP indices and provides us with a clinical insight to 
better incorporate these tools in our routine cardiovascular risk factor management. 
However, these non-invasive devices were not validated to be used for CBP and aortic 
stiffness assessment during AF.  In Chapter 5, we present our findings of IMPULSE AF 
validation study (Trial Id: ACTRN12616001225404). It was the first study to evaluate and 
validate CBP and aortic stiffness assessment during AF. Our results showed a significant 
and strong correlation between invasive and non-invasive CBP recordings during sinus 
rhythm and AF. Additionally, aortic stiffness assessment by carotid-femoral PWV can be 
reliably performed during AF especially when ventricular heart rate can be adequately 
controlled.  
In addition to resting CBP and aortic stiffness assessment, exaggerated BP response to 





Chapter 6 characterises the difference of central and peripheral blood pressure indices 
response to exercise in AF compared to non- AF “controls”. Despite a relatively normal 
resting BP, patients with AF were found to have a residual aortic stiffness, demonstrating 
an advanced central arterial remodelling.  
Aggressive cardiovascular risk factor management has been recognised for its crucial role 
to improve AF outcomes. Hypertension is the most prevalent modifiable factor related to 
AF and needs to better defined. Our work highlighted the role of CBP indices and aortic 
stiffness assessment to better characterise hypertension induced CV remodelling in 
individuals labelled as pre-hypertensives based on conventional brachial BP estimation.  
Additionally, this work has expanded the scope of central pressure wave and velocity 
assessment in AF and during exercise. However, further work is needed to establish CBP 
and aortic stiffness as a treatment target to prevent hypertension induced premature CV 

















This thesis focussed on CBP and aortic stiffness evaluation to improve clinical profiling 
and CV risk management in AF by examining sub-clinical HTN and its associated end organ 
injury. However, few questions remain unanswered, some of which are discussed below.  
The actual prevalence of central high BP and aortic stiffness in AF population is not fully 
known. Specifically, the incidence of central high BP in AF cohort characterised as 
normotensives based on brachial BP assessment has not been explored to date. This 
requires further studies as it may be particularly relevant in younger patients with normal 
LA size and no apparent AF risk factors.  
The correlation between high CBP indices and electro-anatomical left atrial remodelling is 
yet to be fully described. While aortic stiffness and endothelial dysfunction are the 
possible patho-physiological links, further studies are required to better understand the 
underlying mechanisms. This will help affirm AF as a marker of end organ injury in 
hypertensive cohort.  
Early detection of central high BP can help prompt introduction of treatment to preclude 
accelerated cardiovascular and left atrial remodelling. Chapter 4 of this thesis provides a 
comprehensive review of the actual methodology with clinical relevance of non-invasive 





routine clinical practice. Further, in chapter 5 we extended the scope of CBP indices 
assessment during AF by presenting our IMPULSE AF study results. However, this thesis 
did not set out to study the prognostic impact of treating HTN as per CBP targets as a 
primary and secondary preventative strategy in AF.  
In addition, the impact of HTN treatment based on CBP indices on CV outcomes including 
stroke, myocardial infarction, heart failure hospitalisation and renal failure requires 
further evaluation. Similarly, further clinical trials are needed to examine the benefits of 
targeting sub-clinical central vascular remodelling in AF unmasked by CBP indices in 
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